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Abbreviations 
 
ANKTM1  Ankyrin-like protein with transmembrane domains 1 
ANOVA  analysis of variance 
ATP   adenosine triphosphate 
AUC   area under the curve 
BSA   bovine serum albumin 
cAMP   cyclic adenosine monophosphate 
CGRP   calcitonin gene-related peptide 
CRLR   calcitonin receptor-like receptor 
DSS   dextran sulphate sodium 
EC50   half maximal effective concentration 
EDTA   ethylenediamine tetraacetic acid 
EFS   electrical field stimulation 
ELISA   enzyme-linked immunosorbent assay 
IgG   immunoglobuline G 
IL-1 interleukin-1 beta 
LPS   lipopolysaccharide 
MALDI TOF matrix-assisted laser desorption/ionization time of flight mass 
spectrometry 
MPO   myeloperoxidase 
mRNA  messenger ribonucleic acid 
MW   molecular weight 
NK1, 2, 3  neurokinin 1, 2, 3 receptors 
NKA, B  neurokinin A, B 
NO   nitric oxide 
OD   optical density 
PAC1   PACAP type I receptor 
PACAP  pituitary adenylate cyclase activating polypeptide 
PACAP-LI  PACAP-like immunoreactivity 
PKA   protein kinase A 
PKC   protein kinase C 
PMA   phorbol 12-myristate 13-acetate 
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PPT-A, B  preprotachykinin A, B 
RAMP-1  receptor-activity-modifying protein 1 
RIA   radioimmunoassay 
RTX   resiniferatoxin 
SEM   standard error of the mean 
SP   substance P 
TNBS   trinitrobenzene sulphonic acid 
TRPA1  transient receptor potential channel A1 
TRPV1  transient receptor potential vanilloid 1 receptor 
VPAC1, 2  VIP PACAP receptor 1, 2 
VR1   vanilloid receptor subtype 1 
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Introduction 
 
 
Capsaicin-sensitive nociceptive afferent neurons 
 
Nociceptive afferent neurons transport information into the central nervous system 
about potentially noxious stimuli. Somata of nociceptive primary afferent neurons 
innervating the skin are located in dorsal root ganglia and trigeminal ganglia. Cell 
bodies of extrinsic afferent neurons innervating the gastrointestinal tract lie in the 
jugular and nodose ganglia or in the dorsal root ganglia. They reach the central 
nervous system via the vagal and spinal nerves (Grundy, 2002; Holzer, 2002). Axons 
of these neurons are either myelinated (A ) or unmyelinated (C).  
It has been known for a long time that antidromic electrical stimulation of the 
peripheral stumps of afferent nerves of the skin, exteroceptive mucosal areas and 
visceral organs (Lundberg et al., 1984; Szolcsányi, 1984; Koltzenburg & McMahon, 
1986) leads to vasodilatation (Bayliss, 1923; Langley, 1923) and subsequent plasma 
extravasation. This phenomenon is called neurogenic inflammation, because it is 
prevented by desensitization of sensory nerves or denervation (Jancsó et al., 1967; 
Jancsó et al., 1968). The major subpopulation of nociceptive nerve fibres associated 
with this response is selectively excited and, in high dose, desensitized by the 
pungent ingredient of hot chilli pepper, capsaicin, and is now called “capsaicin-
sensitive afferents” (Szolcsányi, 1982; Szolcsányi, 1996).  
Neurogenic inflammation is mediated by sensory neuropeptides released from 
capsaicin-sensitive nerve fibres. Tachykinins (substance P, neurokoinin A and B) are 
responsible for plasma extravasation, mast cell degranulation and leukocyte 
accumulation. Calcitonin gene-related peptide (CGRP) induces vasodilatation 
(Holzer, 1991; Maggi, 1995; Brain 1997). Capsaicin-sensitive afferents also release 
neuropeptides associated with anti-inflammatory actions (somatostatin, galanin, 
PACAP-38), some of them can be detected in the systemic circulation (Szolcsányi et 
al., 1998a). Besides inflammatory actions sensory neuropeptides influence smooth 
muscles of the gastrointestinal tract (Barthó et al., 2004). This means that capsaicin-
sensitive sensory neurons exert triple function: afferent, local efferent (pro-
inflammatory) and systemic efferent (anti-inflammatory) effects.  
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Besides antidromic electrical stimulation capsaicin-sensitive neurons can be 
activated orthodromically by noxious heat, mechanical and chemical stimuli. 
Chemical substances include pungent agents (capsaicin, resiniferatoxin and mustard 
oil) or protons. Capsaicin is the pungent ingredient of red pepper (Capsicum genus). 
It has vanilloid structure (8-Methyl-N-vanillyl-trans-6-nonenamide) and activates 
sensory fibres via transient receptor potential vanilloid 1 (TRPV1) receptors. 
Repeated administration of high doses desensitizes and induces destruction of 
terminal parts of a major subpopulation of nociceptive sensory nerve fibres. Multiple 
application of capsaicin depletes the peptide content of sensory nerve endings 
(Jancsó & Jancsó-Gábor, 1959; Jancsó, 1960; Szolcsányi, 1977; Szolcsányi, 1996). 
Resiniferatoxin (RTX) is the irritant principle of Euphorbia resinifera. It is also a 
vanilloid compound and related to phorbol substances. It activates protein kinase C 
(PKC), but is not tumorigenic. RTX is an ultrapotent capsaicin analogue, which is 
more suitable for desensitization of capsaicin-sensitive nerve fibres because of less 
unwanted effects (Szállási & Blumberg, 1989; Szállási et al., 1990; Szolcsányi et al., 
1990; Szállási & Blumberg, 1999). Plants of the Brassica genus contain mustard oil 
(allyl isothiocyanate). When applied at a concentration below 20% (according to 
other authors below 5%) allyl isothiocyanate selectively excites capsaicin-sensitive 
afferents in rodent skin. Unlike capsaicin, mustard oil does not cause desensitization 
of nerve terminals, so treatment can be performed repeatedly (Jancsó et al., 1967; 
Jancsó et al., 1977; Inoue et al., 1997; Bester et al., 1998; Laird et al., 2000). Mustard 
oil activates TRPA1 (former ANKTM1) receptors, which, like TRPV1 capsaicin 
receptors, are members of transient receptor potential (TRP) receptor superfamily 
(Jordt et al., 2004). 1% mustard oil causes neurogenic inflammation without the 
involvement of mast cells (Inoue et al., 1997; Szolcsányi et al., 1998a).  
Neurogenic inflammation may contribute to the pathomechanism of several diseases 
like bronchial asthma (Barnes, 1986; Bertrand et al., 1993; Germonpré et al., 1995; 
Germonpré et al., 1997), allergic rhinitis (Bertrand et al., 1993; Quartara & Maggi, 
1998), conjunctivitis and dermatitis (Gutwald et al., 1991), ekzema (Naukkarinen et 
al., 1996), rheumatoid arthritis (Levine et al., 1985), migraine (Buzzi & Moskowitz, 
1990; Williamson & Hargreaves, 2001) and inflammatory bowel disease (Renzi et 
al., 2000). Neurogenic component of these conditions can not be relieved by 
orthodox non-steroidal anti-inflammatory agents (Jancsó-Gábor & Szolcsányi, 1972; 
Helyes et al., 2001).  
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TRPV1 capsaicin receptor 
 
The existence of a capsaicin receptor molecule in the cell membrane of a 
subpopulation of nociceptive sensory neurons was put forward long ago (Szolcsányi 
& Jancsó-Gábor, 1975). Recently, the cloning of capsaicin receptor succeeded 
(Caterina et al., 1997; Caterina & Julius, 2001; Clapham et al., 2003). Initially the 
receptor was called vanilloid receptor 1 (VR1). Later homology was found with 
transient receptor potential (TRP) ion channels and the name was modified for 
transient receptor potential vanilloid 1 (TRPV1) (Gunthorpe et al., 2002).  
TRPV1 proteins contain 6 transmembrane domains and four protein subunits form a 
functional non-selective cation channel (Caterina et al., 1997; Caterina et al., 1999; 
Smith et al.,
 
2002; Watanabe et al., 2002). The cation channel can be activated by 
noxious heat (over 43 °C), protons (Tominaga et al., 1998), exogenous compounds 
(capsaicin, resiniferatoxin, piperin, zingerone, gingerol, ethanol) (Szolcsányi, 1983; 
Szállási & Blumberg, 1989; Patacchini et al., 1990; Szállási & Blumberg, 1990; 
Blumberg et al., 1993; Liu & Simon, 1996; Caterina et al., 1997; Szállási & 
Blumberg, 1999; Liu et al., 2000; Dedov et al., 2002), endogenous compounds 
(anandamide, lipoxygenase products, N-oleoyl-dopamine) (Hwang et al., 2000; 
Benham et al., 2002; DiMarzo et al., 2002; Szolcsányi, 2002; Trevisani et al., 2002; 
Chu et al., 2003). TRPV1 receptor can be considered an integrator nociceptive 
transducer membrane protein suitable for signalling of noxious chemical and heat 
stimuli in the peripheral endings of polymodal nociceptors (Tominaga et al., 2001; 
Garcia-Martinez et al., 2002; Szolcsányi & Pethő, 2006).  
Opening of the non-selective TRPV1 ion channel leads to inwardly rectifying Ca
2+
 
and Na
+
 currents. These currents depolarize the neuronal membrane and result in 
action potential formation. Rise of intracellular Ca
2+
 concentration also plays a role 
in the exocytosis of neuropeptides. Elevated intracellular Ca
2+
 level switches on 
several signal transduction pathways that contribute to the desensitization of the 
afferent neuron (Koplas et al., 1997; Liu & Simon, 1998).  
Phosphorylation of TRPV1 protein by various enzymes induces sensitization or 
activation. One of these enzymes is protein kinase C (PKC) (Cesare et al., 1999; 
Chuang et al., 2001; Varga et al., 2006). PKC is a phospholipid-dependent enzyme, 
which plays pivotal role in several signal transduction processes. Activation of PKC 
is implicated in the pathogenesis of inflammation via phospholipase A2-dependent 
 11 
arachidonic acid release and eicosanoid production (Silvan et al., 1996; Bermejo et 
al., 1998). Recent papers have been revealed that PKC activation by phorbol 12-
myristate 13-acetate (PMA) elicited nocifensive behaviours exclusively via 
sensitization/activation of TRPV1 receptors, since the PMA-induced nocifensive 
reaction was completely absent in TRPV1 knockout animals (Bölcskei et al., 2005) 
or TRPV1 receptor antagonists strongly inhibited it (Ferreira et al., 2005).  
 
 
Pro-inflammatory sensory neuropeptides 
 
Main members of pro-inflammatory sensory neuropeptides include tachykinins 
(substance P, neurokinin A, neurokinin B) and CGRP. The tachykinins hemokinin-1 
and endokinins were discovered recently.  
Tachykinins share a common C terminal amino acid sequence. Substance P (SP) was 
isolated by von Euler and Gaddum from the brain and intestine of the horse in 1931. 
Main sources of tachykinins are capsaicin-sensitive sensory neurons, but they can 
also be found in some non-neurogenic elements. Tachykinins were evinced in 
capsaicin-resistant large neurons with A  axons following inflammation-induced 
plasticity (Neumann et al., 1996), in capsaicin-resistant neurons of the airways 
(Hunter et al., 2000), and in the enteric nervous system (Holzer & Holzer-Petsche, 
1997; Lomax & Furness, 2000). SP was also detected in endothelial, inflammatory 
and immune cells (Aliakbari et al., 1987; Linnik & Moskowitz, 1989; Pascual & 
Bost, 1990; Ho et al., 1997; Maggi, 1997; Lai et al., 1998). SP and neurokinin A 
(NKA) are translated from preprotachykinin A gene (PPT-A), whereas neurokinin B 
(NKB) is translated from preprotachykinin B gene (PPT-B). Tachykinins activate G 
protein coupled receptors (NK1, 2, 3). NK1 receptor is present both in the central and 
peripheral nervous systems. It was also detected on endothelial and smooth muscle 
cells (Patacchini & Maggi, 2001). Inducible form of NK1 receptor is expressed in 
bone marrow cells (Bandari et al., 2003). NK2 receptor is mostly located in the 
periphery, but it can be found in some nuclei of the central nervous system. NK3 
receptor is mainly present in the central nervous system and in some peripheral 
organs, such as the uterus, striated muscles, lungs, the liver, portal and mesenteric 
veins, enteric neurons (Tsuchida et al., 1990; Massi et al., 2000). SP, NKA and NKB 
are all full agonists of NK1, 2 and 3 receptors. SP has the highest affinity to NK1, 
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NKA to NK2 and NKB to NK3 receptors. The recently discovered hemokinin-1, 
endokinin A and B are also full agonists of NK1, 2 and 3 receptors. Endokinin A and 
B may be the endogenous ligands of NK1 receptors in the non-innervated areas 
(Page et al., 2003).  
Tachykinins mediate diverse effects. Tachykinins released in the dorsal root of the 
spinal horn contribute to pain sensation. They also modulate cholinergic and 
adrenergic neurotransmission (Grant, 2002). Tachykinins induce endothel-dependent 
vasodilation via NK1 receptor. They facilitate proliferation, migration of endothelial 
cells and angiogenesis (Maggi, 1995). In some vascular areas tachykinins cause 
vasoconstriction via NK1, 2 and 3 receptors. Tachykinins evoke plasma protein 
extravasation in both somatic and visceral areas by activating NK1 receptors. 
Smooth muscle contraction can be produced by tachykinins indirectly, via release of 
other mediators and mast cell degranulation. They can also contract smooth muscles 
directly. NK1 and 2 receptors were evinced in the smooth muscles of several organs 
(Maggi, 1991, 1995). Mast cell degranulation by SP was thought to be evoked by 
basic amino acids of the N terminal (Maggi, 1997). Recently, NK1 receptors were 
found in mast cells (Cao et al., 1999). SP stimulates the secretion of salivary, 
intestinal glands and the pancreas (Lembeck & Starke, 1968; Konturek et al., 1981).  
CGRP was discovered by Amara and co-workers (Amara et al., 1982). It exists in 
two variant forms ( CGRP and CGRP) which are produced by alternative splicing. 
CGRP belongs to the calcitonin/CGRP peptide family, other members of which are 
islet amyloid polypeptide and adrenomedullin. CGRP acts via G protein coupled 
receptors. CGRP receptor consists of calcitonin receptor-like receptor (CRLR) and 
receptor-activity-modifying protein 1 (RAMP-1) (Njuki et al., 1993; McLatchie et 
al., 1998).  
CGRP has mostly extraneural effects. It facilitates the release of acethylcholine from 
the myenteric plexus of the guinea pig ileum, but inhibits the release of noradrenaline 
and ATP. CGRP applied intravenously causes hypotension, tachycardia, enhanced 
coronary and mesenteric blood flow due to vasodilation. This vasodilation is 
independent of endothelial cells and represents direct action on smooth muscle cells 
(Edvinsson et al., 1985; Han et al., 1990; Hughes & Brain, 1994). However, dilation 
of the aorta is endothelium-dependent and is mediated via nitric oxide (NO) (Brain et 
al., 1985; Gray & Marshall, 1992). Another possible mechanism of CGRP-evoked 
vasodilation is activation of ATP-sensitive potassium channels by the protein kinase 
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A (PKA) pathway (Nelson et al., 1990; Quayle et al., 1994; Brain & Grant, 2004). 
Vasodilatatory effect of CGRP can be detected mainly on arteries and arterioles. 
CGRP itself does not enhance vascular permeability, but potentiates the action of SP 
(Cao et al., 2000). Similarly to the vasodilatatory effect, CGRP induces smooth 
muscle relaxation in several organs (Maggi, 1995). CGRP exerts positive 
chronotropic and inotropic actions on the heart due to elevation of cAMP level 
(Tippins et al., 1984). Under in vitro conditions CGRP facilitated attachment of 
neutrophils to vascular endothelium by raising the expression of adhesion molecules 
(Hartung & Toyka, 1989). However, CGRP diminished maturation of pre-B 
lymphocytes, their immunoglobuline production and proliferation of T lymphocytes. 
CGRP inhibited the secretion of pro-inflammatory cytokines (IL-1, IL-12) by 
macrophages, but facilitated the production of the anti-inflammatory IL-10. These 
data demonstrate that CGRP may have anti-inflammatory properties when disease is 
mainly mediated by lymphocytes and macrophages.  
 
 
PACAP-38 and capsaicin-sensitive primary afferent neurons 
 
Sensory ganglia contain several peptides, but not all of them have real functional 
significance in sensory-mediated processes (Hökfelt et al., 1976; Maggi, 1995). 
Pituitary adenylate cyclase activating polypeptide (PACAP) is a member of the 
vasoactive intestinal peptide (VIP)/secretin/glucagon peptide family and was 
originally isolated from ovine hypothalamus (Miyata et al., 1989). PACAP exists in 
two forms (PACAP-27 and PACAP-38). The 38 amino acid form is the predominant 
in mammalian tissues.  
Two types of PACAP binding sites were evidenced in different tissues. Type I 
binding sites have high affinity for PACAP-38 and 27, but low affinity for VIP (Suda 
et al., 1992). Type II binding sites have similar affinity for PACAP and VIP 
(Gottschall et al., 1990; Lam et al., 1990). Type I binding sites represent PAC1 
receptors which are specific for PACAP (Pisegna & Wank, 1993). Type II biding 
sites represent VPAC1 and 2 receptors which bind PACAP and VIP, too (Ishihara et 
al., 1992; Lutz et al., 1993; Arimura, 1998; Sherwood et al., 2000; Vaudry et al., 
2000). The receptors of PACAP are G protein-coupled receptors. PACAP receptors 
are widely distributed throughout the central nervous system and peripheral organs. 
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PAC1 receptor is the predominant form in the brain. Its mRNA was detected in the 
olfactory bulb, the dentate gyrus of the hippocampus, the supraoptic nuclei of the 
hypothalamus, the cerebellar cortex and area postrema (Hahsimoto et al., 1996; 
Nomura et al., 1996; Shioda et al., 1997; Otto et al., 1999). VPAC1 receptor mRNAs 
were identified in the cerebral cortex and the hippocampus. VPAC2 mRNAs were 
found in the thalamus, the suprachiasmatic nucleus, the central nucleus of the 
amygdala and the pontine nucleus (Usdin et al., 1994; Sheward et al., 1995). VPAC1 
and 2 mRNAs overlap only in the hippocampus (Usdin et al., 1994). PACAP 
receptors are located both on neurons and glial cells (Tatsuno et al., 1991; Grimaldi 
& Cavallaro, 1999). Messenger RNAs of PACAP binding receptors were detected in 
most endocrine glands including the pituitary, the pancreas, the adrenal gland and 
gonads (Usdin et al., 1994; René et al., 1996). They were also demonstrated in the 
alimentary canal and accessory glands, the respiratory tract, the cardiovascular 
system, the kidneys, white fat and skeletal muscles (Ishihara et al., 1992; Usdin et al., 
1994; Wei & Mojsov, 1996; Wong et al., 1998). Macrophages and lymphocytes 
express PACAP receptors, too (Delgado et al., 1996; Johnson et al., 1996).  
PACAP occurs in the central and peripheral nervous system, endocrine glands, 
cardiovascular, respiratory and gastrointestinal tracts. PACAP has diverse actions in 
the central and peripheral nervous systems and also in peripherwal tissues 
(Somogyvári-Vigh & Reglődi, 2004; Zhou et al., 2002). PACAP is reported to 
regulate cell division, cell cycle arrest, differentiation and cell death. It seems to have 
a protective function in neurons, but it promotes apoptosis in tumor cells (Spengler et 
al., 1997; Gillardon et al., 1998). PACAP plays an important role in the development 
of the brain, the liver, the adrenal gland and the pancreas (Le Meuth et al., 1991; El 
Fahime et al., 1996; DiCicco-Bloom et al., 1998; Yon et al., 1998). PACAP and its 
various receptor forms are found in many cancers. They are involved in both 
proliferation and differentiation. PACAP exerts primariliy relaxant effect on blood 
vessels. Although, fall of blood pressure induced by intravenous administration of 
PACAP is followed by an increase in cats and dogs (Ishizuka et al., 1992). The 
secondary vasoconstriction may result from sympathetic regulation, differential 
receptor use, PACAP-induced arginine vasopressin or catecholamine release. 
PACAP evokes smooth muscle relaxation in the respiratory, digestive and 
reproductive organs. It has positive inotropic, chronotropic and dromotropic effects 
in the heart. PACAP participates in immune cell protection, phagocytosis and 
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immune response. It plays a role in bone formation (Strange-Vognsen et al., 1997), 
resorption (Winding et al., 1997) and haematopoiesis (Cai et al., 1997). PACAP 
regulates endocrine functions of the hypothalamus, the pituitary, gonads, the adrenal 
gland, the pancreas and enterochromaffin-like cells of the gastrointestinal tract. It 
influences exocrine secretion of the stomach, the pancreas and seromucous glands 
(Cardell et al., 1991; Raufman et al., 1991; Felley et al., 1992; Mungan et al., 1995; 
Onaga et al., 1996). PACAP stimulates melatonin synthesis in the pineal gland 
(Simonneaux et al., 1998). The level of PACAP in retinal ganglion cells is low in the 
day and high at night (Fukuhara et al., 1997). PACAP takes part in the regulation of 
autonomic functions associated with the medulla oblongata, otic ganglia, 
sphenopalatine ganglia and the jugular nodose ganglia (Legradi et al., 1994; Mulder 
et al., 1995). Presence of PACAP in ciliary ganglion neurons, jugular and nodose 
ganglia, dorsal horn neurons, spinal cord, mesencephalic trigeminal nucleus and the 
vagal nerve indicate its role in sensory neurotransmission (Mulder et al., 1995; 
Zhang et al., 1995; Dickinson et al., 1997; Larsen et al., 1997; Zhang et al., 1997; 
Reimer et al., 1999). PACAP may have a stress-related behavioural function (Kozicz 
et al., 1997). It is involved in behaviour associated with increased grooming, pain 
responses, reduced food intake, motor activity and body temperature (Morley et al., 
1992; Masuno et al., 1995; Narita et al., 1996; Zhang et al., 1996; Masuno et al., 
1997; Mizuno et al., 1998). It enhances rapid eye movement sleep. This is partly due 
to facilitation of prolactin secretion (Bredlow et al., 1994; Fang et al., 1995).  
As mentioned above, presence of PACAP-like immunoreactivity was evidenced in 
the superficial dorsal spinal horn layers and in small-sized neurons of the dorsal root 
ganglia (Moller et al., 1993; Mulder et al., 1994; Dun et al., 1996). PACAP was also 
detected in a population of capsaicin-sensitive sensory neurons (Zhang et al., 1996). 
In sensory ganglia, nerve plexus of inner organs (Fahrenkrug & Hannibal, 1998; 
Hannibal et al., 1998; Skakkebaek et al., 1999; Hannibal & Fahrenkrug, 2000; 
Schoenfeld et al., 2000), pineal gland (Moller et al., 1999), skin and in teeth 
(Ichikawa & Sugimoto, 2003) PACAP-38 coexists with CGRP. The coexistence of 
PACAP and SP has also been reported (Strange-Vognsen et al., 1997; Schoenfeld et 
al., 2000; Mirabella et al., 2001).  
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Aims 
 
We planned to investigate the role of capsaicin-sensitive afferent nerve terminals and 
TRPV1 receptors in different animal models of inflammation. In particular, we were 
interested in sensory neuropeptides that may have systemic anti-inflammatory 
properties. We performed both in vitro and in vivo experiments using systemic 
desensitization of capsaicin-sensitive nerves and TRPV1 receptor gene knockout 
animals. Our goals were the following: 
1. We would like to clarify whether PACAP-38 can be released from capsaicin-
sensitive primary afferents in response to electrical and chemical stimuli 
under in vitro conditions.  
2. We also would like to examine if PACAP-38 can be released from capsaicin-
sensitive afferents in vivo and if it can reach the systemic circulation.  
3. Our aim was to study the effect of systematically applied PACAP-38 on 
different animal models of inflammatory disease. These include both 
neurogenic and mixed type inflammatory conditions.  
4. We would like to analyze the participation of capsaicin-sensitive nerve 
terminals and TRPV1 receptors in the sensitizing effect of PMA-induced ear 
inflammation.  
5. We would like to investigate the role of prostanoids and IL-1  in the 
sensitizing effect of PMA-evoked ear inflammation.  
6. Our aim was to determine the function of capsaicin-sensitive afferents and 
TRPV1 receptors in DSS-induced colonic inflammation.  
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Effect of PACAP-38 on sensory neuropeptide release, acute 
neurogenic and non-neurogenic inflammatory processes in 
rats and mice 
 
 
Introduction 
 
 
Numerous studies suggest that PACAP has immunomodulatory actions, which 
together with those of VIP are mainly anti-inflammatory (Delgado et al., 1999a; 
Abad et al., 2001; Abad et al., 2006; Gomariz et al., 2006). Relatively little is known 
about the actions of PACAP on neurogenic components of inflammation. 
There are two sources of PACAP in the immune system: neurons innervating the 
lymphoid organs and immune cells themselves. PACAP is produced by B and T 
lymphocytes, but not by peritoneal macrophages (Gaytan et al., 1994; Abad et al., 
2002). Expression of PACAP receptors has been demonstrated in most immune cell 
types. B and T cells express VPAC1 and 2 receptors. Macrophages express PAC1, 
VPAC1 and 2 receptors (Pozo et al., 1997; Qian et al., 2001). VPAC2 is inducible in 
T cells and macrophages (Delgado et al., 1999b). Most important anti-inflammatory 
effect of PACAP is direct inhibition of macrophage activity (Delgado et al., 1999b). 
It also stimulates the secretion of anti-inflammatory cytokines (Delgado et al., 1999c) 
and down-regulates the expression of the macrophage co-stimulatory molecules B7.1 
and B7.2 (Greenwald et al., 2005). PACAP may stimulate or inhibit the secretion of 
immunoglobulines depending on the source of B lymphocytes and the 
immunoglobuline isotype (Delgado et al., 2004). It also diminishes neutrophil 
chemotaxis (Kinhult et al., 2001). PACAP promotes Th2 differentiation above Th1 
responses. This involves impeding signalling molecules that facilitate Th1 reaction 
(IL-12) and selective generation of Th2 memory cells (Delgado et al., 2000; Delgado 
et al., 2002).  
These data prognosticate a beneficial effect of PACAP in inflammatory diseases 
characterized by macrophage overactivity and an overbalanced Th1/Th2 response. 
Animal models of inflammation in which PACAP was successfully applied include 
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LPS-induced septic shock, asthma models, collagene-induced arthritis, experimental 
autoimmune encephalomyelitis and brain injury (Saotome et al., 1998; Delgado et 
al., 1999d; Abad et al., 2001; Kato et al., 2004).  
Because lack of data about actions of PACAP in neurogenic inflammatory processes, 
we focused our experiments on this field.  
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Methods 
 
 
Animals 
 
Experiments were carried out on male Wistar rats and Balb/c mice. Animals were 
bred in the Animal House of Pécs University under pathogen free condition at 24-25 
ºC in climatically controlled environment, given standard diet and water ad libitum.  
 
 
Measurement of capsaicin-evoked and electrically-induced sensory 
neuropeptide release from isolated rat tracheae 
 
Rats were exsanguinated in deep anaesthesia (thiopental sodium, 50 mg/kg i.p.). The 
whole trachea was removed. Tracheae from two rats were placed into the same organ 
bath (1.8 ml) and perfused (1 ml/min) with pH 7.2 oxygenized Krebs solution for 60 
min at 37 
o
C. After the equilibration period pre-stimulated, stimulated and post-
stimulated fractions were collected, 8 min each. In the second electrical field 
stimulation (EFS; 40 V, 0.1 ms, 10 Hz for 120 s; 1200 pulses) was performed or 
capsaicin (10
-6
 M) was added into the medium.  
PACAP-38, CGRP, substance P and somatostatin concentrations were determined from 
the incubation medium by radioimmunoassay (RIA) (Németh et al., 1996; Helyes et al., 
1997; Németh et al., 1998; Németh et al., 1999; Jakab et al., 2004). For the specific 
RIA assays the antisera (PACAP-38: “88111-3”; SP: “L83”; CGRP: “C1012”; 
somatostatin: “775/7”) were raised in rabbits or, in case of somatostatin, in sheep 
immunised with synthetic peptides conjugated to bovine serum albumin or 
thyroglobulin by glutaraldehyde or carbodiimide. The tracers were mono-
125
I-
labelled peptides. Synthetic peptides were used as standards.  
The assay was prepared in 1 ml 0.05 mol/l, pH 7.4 phosphate buffer containing 0.1 
mol/l sodium chloride, 0.25% BSA and 0.05% sodium aside. The antiserum (100 l, 
1:10000), the RIA tracer (100 l, 5000 cpm/tube) and the standard or unknown 
samples (100 l) were put into the assay buffer. After 48-72 h incubation at 4 C, the 
antibody-bound peptide was separated by adding 100 l separating solution (10 g 
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charcoal, 1 g dextran and 0.5 g fat-free milk powder in 100 ml distilled water). 
Following centrifugation (3000 rpm, 4 C, 15 min) the radioactivity of the 
precipitates was measured. Peptide concentrations of the unknown samples were 
calculated from a calibration curve.  
To examine the effect of PACAP-38 on the release of the sensory neuropeptides it was 
added into the incubation medium at the beginning of each 8 min fraction in 
concentrations of 20, 100, 500 and 2000 nM.  
 
 
Identification of PACAP-38 from the plasma with mass spectrometry 
 
Identification of PACAP-38 from plasma samples in comparison to standard 
PACAP-38 peptide was performed with matrix–assisted laser desorption ionization 
time of flight (MALDI TOF) mass spectrometry to demonstrate that the plasma 
samples contain PACAP-38 and do not contain PACAP-27. The aqueous solutions of 
the PACAP-38 standard and the naïve rat serum sample were loaded onto the target 
plate by mixing 1 µl of each solution with the same volume of saturated matrix 
solution. The ions were accelerated under delayed extraction conditions (200 ns) in 
positive ion mode with a voltage of 20 kV. Each spectrum was detected in linear 
mode. The instrument uses a 337 nm pulsed nitrogen laser. External calibration was 
performed in each case using Bruker Peptide Calibration Standard. Protein masses 
were acquired with a range of 1000 to 8000 m/z. Each spectrum was produced by 
accumulating data from 300 consecutive laser shots.  
 
 
Systemic stimulation of capsaicin-sensitive afferents in vivo 
 
Tail veins of anaesthetized rats (thiopental sodium, 100 mg/kg, i.p.) were cannulated 
and resiniferatoxin, an ultra-potent TRPV1 receptor agonist was administered (3 
g/kg, i.v.) (Szállási & Blumberg, 1989; Helyes et al., 2003). Tracheal T-cannula 
was inserted for artificial respiration when required. Blood samples were taken by 
cardiac puncture 5 min after RTX injection.  
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Antidromic stimulation of the sciatic nerve 
 
Electrical stimulation of peripheral stumps of cut sciatic nerves of anaesthetized rats 
(thiopental sodium, 100 mg/kg, i.p.) was performed (20 V, 0.5 ms, 5 Hz, 5 min) 
(Szolcsányi et al., 1998b). Guanethidine (8 mg/kg, i.p.) was administered 1 h before 
nerve excitation to counteract the vascular effects of sympathetic nerve activation. 
Pipecuronium bromide (200 μg/kg, i.v.) was injected to block neuromuscular 
transmission and positive pressure ventilation was carried out through a T tracheal 
tube with room air. Tidal volume was set for 10 ml/kg and respiratory rate was 
adjusted to 100 cycles/min. Blood samples were taken by cardiac puncture 5 min 
after the end of the stimulation period.  
 
 
Plasma preparation for radioimmunoassay 
 
Plasma concentration of PACAP-38 was determined by RIA (Jakab et al., 2004). 
Blood samples (6 ml per animal) were taken by cardiac puncture and mixed with 
EDTA (12 mg) and aprotinin (1200 U). Following centrifugation (2000 rpm for 10 
min at 4 C) the peptide was extracted from the plasma by addition of 3 volumes of 
absolute alcohol. After second centrifugation (2000 rpm for 10 min at 4 C) the 
samples were dried under nitrogen flow and resuspended in 300 l assay buffer 
(Jakab et al., 2004). RIA was performed as described above.  
 
 
Measurement of mustard oil-induced neurogenic oedema formation in the 
mouse ear 
 
Male Balb/c mice (20-25 g) were anaesthetized with ketamine (100 mg/kg, i.p.) and 
xylazine (5 mg/kg, i.p.). Neurogenic ear swelling was evoked by topical application 
of 10 l of 1% mustard oil dissolved in liquid paraffin on the inner and outer surfaces 
of both ears at the beginning of the experiment and 1 h later. Ear thickness was 
measured with an engineers’ micrometer (0.01 mm accuracy) before the treatment 
and 4 times during the 3 h examination period. Oedema was expressed in % 
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compared to the initial control values. PACAP-38 (10, 100 and 1000 g/kg in 200 l 
saline, i.p.) was administered 15 min before both mustard oil smearing. Animals of 
the control group were treated with the same volume of saline. The assigned PACAP 
dose was based on earlier studies (Abad et al., 2001; Kato et al., 2004). Area under 
the curve (AUC) values were calculated (arbitrary units are mm x min) and analyzed.  
At the end of the experiment mice were sacrificed by anaesthetic overdose, the ears 
were dissected and histology was performed. Oedema formation in the connective 
tissue was evaluated.  
 
 
Measurement of mustard oil-induced acute neurogenic inflammation in the skin 
of the rat hindpaw 
 
Both hindlegs of male Wistar rats weighing 180-250 g were acutely denervated (the 
sciatic and the saphenous nerves were cut 30 min before the induction of 
inflammation) under pentobarbital sodium (40 mg/kg, i.p.) anaesthesia to avoid 
central reflexes. Acute neurogenic inflammation in the paw skin was evoked by 
topical application of 1% mustard oil dissolved in paraffin oil. Extravasation of 
plasma albumin was measured by the Evans blue leakage method. Evans blue (50 
mg/kg) was injected i.v. and neurogenic inflammation was induced 10 min later. Rats 
were killed by exsanguination 20 min after mustard oil application. The skin of the 
hindpaws was removed and the extravasated dye was extracted with formamide. Dye 
concentration was determined by spectrophotometry at 620 nm and was expressed as 
g dye/g wet tissue (Helyes et al., 1997; Helyes et al., 2001). PACAP-38 (100 g/kg, 
i.p.) was administered 20 min before the induction of inflammation. This systemic 
dose was chosen on the basis of the results of the mouse ear neurogenic oedema 
studies.  
 
 
Measurement of acute neurogenic inflammation evoked by TRPV1 receptor 
agonists in the plantar skin of the rat hindpaw 
 
Both hindlegs of the anaesthetized (pentobarbital sodium, 40 mg/kg, i.p.) rats were 
acutely denervated as described abobe. Acute neurogenic inflammation was evoked 
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by intraplantar injection of RTX (100 l, 0.1 g/ml) or in another group capsaicin 
(100 l, 100 g/ml) into the left hindpaw. Extravasation of plasma albumin was 
measured by the Evans blue leakage method, as described above. Rats were 
exsanguinated 20 min after the application of RTX or capsaicin. The plantar skin of 
the hindpaws was removed and the extravasated dye was extracted, dye 
concentration was measured and expressed as g dye/g wet tissue. Dye content of the 
skin of the right paw was taken off the values. PACAP-38 (10 g/kg) or in the 
control group isotonic saline were administered i.p. 10 min before the induction of 
the inflammation.  
 
 
Measurement of carrageenan-induced oedema formation in the rat hindpaw 
 
Carrageenan (50 l, 3%) was injected intraplantarly into the left hindpaw of 
anaesthetized rats. The volume of the paw was measured with plethysmometry 
before and 60, 120, 180 min after carrageenan administration (Helyes et al., 2006). 
Oedema was expressed as % of initial values. In a group of rats 10 g/kg PACAP-38 
was administered i.p. 10 min before the induction of the inflammation (Helyes et al., 
2001; Helyes et al., 2006). Animals of the control group received saline.  
 
 
Statistics 
 
Results are expressed as mean ± standard error of mean (SEM). For analyzing data 
Student’s t-test and ANOVA followed by Bonferroni’s or Dunnett’s test were used. 
Probability values p<0.05 were accepted as significant.  
 
 
Ethics 
 
All experimental procedures were carried out according to the 1998/XXVIII Act of 
the Hungarian Parliament on Animal Protection and Forbearance and Consideration 
Decree of Scientific Procedures of Animal Experiments (243/1988) and complied 
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with the recommendations of the Helsinki Declaration. The studies were approved by 
the Ethics Committee on Animal Research of Pécs University according to the 
Ethical Codex of Animal Experiments.  
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Results 
 
 
PACAP-38 is released from sensory nerve endings of the isolated rat trachea 
 
Capsaicin (10
-6
 M) and electrical field stimulation (EFS) with C-fibre strength 
evoked 27% and more than two-fold elevation of PACAP-38 release, compared to 
the pre-stimulated basal values, respectively. Post-stimulation levels returned to the 
basal concentrations (Fig. 1).  
 
 
PACAP-38, but not PACAP-27 can be detected in the plasma with mass 
spectrometry 
 
PACAP-38 could be clearly identified in the plasma samples of naїve rats with mass 
spectrometry at the molecular weight signal of 4558.7 Da representing the 
quasimolecular ion of PACAP-38 Na
+
 adduct (MW: 4558.7) which is identical to 
PACAP-38 H
+
 adduct (MW: 4535.03) found in the standard. The other biologically 
active form, PACAP-27 (MW: 3147.6) or its [M+Na]
+
could not be detected (Fig. 3).  
 
 
PACAP-like immonoreactivity of the rat plasma increases in response to systemic 
stimulation of capsaicin-sensitive nerves 
 
Stimulation of capsaicin-sensitive nerves throughout the body by injection of the 
TRPV1 receptor agonist RTX (3 g/kg i.v.) induced a 2-fold elevation of plasma 
PACAP-like immunoreactivity (PACAP-LI) compared to solvent-treated rats. 
Antidromic electrical excitation of the peripheral stump of the cut sciatic nerve 
slightly elevated PACAP-LI, but this local stimulation of cutaneous sensory fibres 
was not sufficient to significantly increase PACAP-LI in the systemic circulation 
(Fig. 2).  
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Figure 1. Release of 
PACAP-38 from 
isolated rat tracheae in 
response to capsaicin- 
and electrical field 
stimulation (EFS; 40 V, 
0.1 ms, 10 Hz, 2 min). 
Each column represents 
the mean±SEM 
concentration of 
PACAP measured in the 
incubation medium of 
the pre-stimulated, 
stimulated and post-
stimulated fractions of 
n=6 experiments (6x2 
tracheae). **P<0.01 vs. 
pre-stimulated fractions 
(Student’s t-test for 
paired comparison).  
 
 
 
 
Figure 2. PACAP-like 
immunoreactivity 
(PACAP-LI) in the rat 
plasma. Plasma 
PACAP-LI significantly 
elevated 5 minutes after 
systemic stimulation of 
capsaicin-sensitive 
sensory nerves by i.v. 
injection of the ultra-
potent TRPV1 receptor 
agonist resiniferatoxin 
(RTX; 3 g/kg). 
However, local 
excitation of capsaicin-
sensitive afferents 
innervating 
predominantly the 
plantar regions of the 
paw (antidromic 
electrical stimulation of 
the peripheral stump of 
the sciatic nerve) 
slightly, but not 
significantly increased 
plasma PACAP-LI. 
Each column represents 
the mean±SEM 
PACAP-LI of n=6 rats. 
**P<0.01 vs. stimulated 
(Student’s t-test for 
unpaired comparison).  
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Figure 3. (a) Identification of PACAP-38 in the standard and (b) in plasma samples of naïve rats with 
mass spectrometry at the molecular weight signal of 4558.7 Da representing the quasimolecular ion of 
PACAP-38 Na
+
 adduct (MW: 4558.7) which is identical to PACAP-38 H
+
 adduct (MW: 4535.03) 
found in the standard. The other biologically active form, PACAP-27 (MW: 3147.6) or its [M+Na]
+ 
could not be detected. (c) Mass spectrum obtained with MALDI TOF/TOF measurement after on-
plate tryptic digestion of PACAP-38 in the plasma samples.  
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PACAP-38 inhibits capsaicin- and EFS-evoked substance P, CGRP and 
somatostatin release from isolated rat tracheae 
 
Capsaicin (10
-6
 M) induced a 2.5-, 11- and 3-fold elevation of substance P, CGRP and 
somatostatin release, respectively. Similarly, EFS (1200 pulses) evoked a 3-, 3.5- and 
2.5-fold increase in the outflow of these peptides. PACAP-38 (20-2000 nM) 
significantly and concentration-dependently inhibited the release of all the three 
measured sensory neuropeptides in both cases. However, it did not influence basal 
peptide release (Fig. 4, 5). The maximal inhibitory effects of PACAP-38 on capsaicin-
induced substance P, CGRP and somatostatin release amounted to 75.4%, 73.3% and 
90.0%. In case of EFS-evoked release the maximal inhibition was 80.0%, 87.7% and 
67.7%. In case of capsaicin stimulation the EC50 values with 95% confidence intervals 
for substance P, CGRP and somatostatin were 82.9 nM (45.3-151.0 nM), 60.1 nM 
(22.9-157.2 nM) and 66.9 nM (13.3–135.8 nM), respectively. When EFS was 
performed, these corresponding EC50 data were 92.1 nM (9.9–185.1 nM), 67.8 nM 
(30.6–150.3 nM) and 20.9 nM (0.5–88.1 nM) (Fig. 6).  
 
 
Effect of PACAP-38 on acute neurogenic oedema of the mouse ear 
 
In the control group ear thickness increased from 258±15 m to 375±24 m within 3 
h in response to topical application of 1% mustard oil. PACAP-38 (10, 100 and 1000 
g/kg) significantly diminished mustard oil-induced ear swelling in a dose-
dependent manner. The highest applied dose completely abolished the oedema 
response (Fig. 7). The AUC value calculated on the basis of the time course of ear 
swelling was 654.2±36.5 units in the control group. Corresponding data in mice 
treated with 10, 100 and 1000 g/kg PACAP-38 were 327.2±23.6, 174.2±12.3 and 
9.5±3.6, respectively, all significantly smaller than the control (Fig. 7).  
Qualitative histological evaluation of the ears showed that 1% mustard oil smearing 
induced marked oedema formation after 3 hours without significant accumulation of 
leukocytes. Dose-dependent inhibitory effect of i.p. PACAP-38 on the development 
of the oedema could also be observed in these histological slides supporting the 
results of the in vivo ear thickness measurement.  
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Figure 4. Effect of PACAP-38 on capsaicin-induced release of substance P, CGRP and somatostatin 
from isolated rat tracheae. Each column represents the mean±SEM concentration of the respective 
peptide measured in the incubation medium of the pre-stimulated, stimulated and post-stimulated 
fractions of n=6 experiments (6x2 tracheae). *P<0.05, **P<0.01, ***P<0.001 vs. control stimulated 
values (Student’s t-test for unpaired comparison).  
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Figure 5. Effect of PACAP-38 on electrical field stimulation (EFS; 40 V, 0.1 ms, 10 Hz, 2 min)-
induced release of substance P, CGRP and somatostatin from isolated rat tracheae. Each column 
represents the mean±SEM concentration of the respective peptide measured in the incubation medium 
of the pre-stimulated, stimulated and post-stimulated fractions of n=6 experiments (6x2 tracheae). 
*P<0.05, **P<0.01, ***P<0.001 vs. control stimulated values (Student’s t-test for unpaired 
comparison).  
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Figure 6. Concentration-response curves demonstrating the inhibitory effect of PACAP-38 on (a) 
capsaicin- and (b) electrical field stimulation (EFS)-evoked release of substance P, CGRP and 
somatostatin from isolated rat tracheae. Concentration of the peptide in the basal, pre-stimulated 
fraction was subtracted from both the respective stimulated and post-stimulated fractions and then 
these values were added providing a total stimulation-evoked release. Inhibition evoked by the 
highest, 2000 nM concentration was considered to be 100% and data points representing mean±SEM 
relative inhibitory effects (%) were calculated by comparing the results of the studies with PACAP-38 
to the control experiments, n = 6.  
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Effect of PACAP-38 on acute neurogenic inflammation in the skin of the rat 
hindpaw 
 
Mustard oil-induced Evans blue dye accumulation, as an indicator of neurogenic 
plasma protein extravasation, in the skin of the acutely denervated rat hindpaw was 
302.7±20.5 g/g wet tissue in the control group. PACAP-38 (100 g/kg, i.p.) exerted 
significant, 37.8% inhibition of this neurogenic inflammatory response: Evans blue 
content of the skin was 200.2±20.4 g/g.  
 
 
PACAP-38 inhibits capsaicin- and resiniferatoxin-induced acute neurogenic 
inflammation in the plantar skin of the rat hindpaw  
 
In the control group Evans blue dye accumulation in the plantar skin of the acutely 
denervated rat hindpaw was 559.1±74.6 g/g
 
 and 590.3 g/g wet tissue in response 
to 100 l intraplantar RTX (0.1 g/ml) and capsaicin (100 g/ml), respectively. Pre-
treatment with PACAP-38 (10 g/kg i.p.) 10 min before the induction of the 
inflammation exerted 45.7% and 46.4% inhibition on these neurogenic inflammatory 
responses (Fig. 8). 
 
 
Effect of PACAP-38 on carrageenan-evoked acute paw oedema in the rat 
 
Intraplantar injection of 100 l 3% carrageenan induced 43.2%, 50.1% and 57.6% 
paw swelling in saline-treated rats at 60, 120 and 180 min, respectively. 
Carrageenan-induced oedema formation was significantly inhibited by 10 g/kg
 
PACAP-38 i.p. at each time point (Fig. 9). Area under the time-dependent percentage 
paw swelling curves (AUC) was 65.6±5.1 units in the saline-treated group and 
39.9±3.2 units in rats treated with PACAP-38.  
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Figure 7. Effect of 
PACAP-38 on mustard 
oil-induced ear swelling 
of the mouse. Mustard 
oil (1% dissolved in 
paraffin oil) was applied 
topically to the outer 
and inner surfaces of 
both ears at the 
beginning of the study 
and 1 h later. PACAP-
38 was injected i.p. (10, 
100 and 1000 g/kg in 
200 l volume) 15 min 
before both mustard oil 
smearing. Data are 
shown as means±SEM 
of percentage increase 
of ear thickness 
compared to the initial 
control diameters. 
Statistical comparisons 
between PACAP-38- 
and saline-treated 
animals were made by 
ANOVA followed by 
Dunnett’s post test, 
n=12 per group, 
*P<0.05, **P<0.01, 
***P<0.001 vs. saline-
treated control.  
 
 
Figure 8. Effect of 
PACAP-38 (10 g/kg 
i.p.) on Evans blue 
accumulation as an 
indicator of neurogenic 
plasma extravasation in 
the plantar skin of the 
acutely denervated rat 
hindpaw induced by 
intraplantar injection of 
100 l capsaicin (100 
g/ml) or resiniferatoxin 
(RTX; 0.1 g/ml). Each 
column represents the 
mean±SEM of n=6 rats. 
*P<0.05, **P<0.01 vs. 
saline-treated control 
(one-way ANOVA 
followed by 
Bonferroni’s test).  
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Figure 9. Effect of 
PACAP-38 (10 g/kg 
i.p.) on carrageenan 
(100 l 3%)-evoked 
paw oedema of the rat 
60, 120 and 180 minutes 
after the induction of 
inflammation. In the 
control group of rats the 
same volume of saline 
was given. Symbols 
indicate % increase of 
the volume of the 
hindpaws as compared 
to the initial values 
measured with 
plethysmometry before 
carrageenan injection. 
Each data point 
represents the 
mean±SEM of n=6 
experiments. *P<0.05, 
**P<0.01 vs. control 
(one-way ANOVA 
followed by 
Bonferroni’s modified t-
test).  
 
 35 
Discussion 
 
Although immunolocalization of PACAP-38 has been described in capsaicin-
sensitive neurons of various species (Moller et al., 1993, Mulder et al., 1994), data 
about its release and function are ambiguous. PACAP-38 is released by electrical 
nerve stimulation and capsaicin in the porcine antrum (Tornoe et al., 2001) and in the 
rabbit eye (Wang et al., 1995; Wang et al., 1997). In vivo capsaicin-evoked PACAP 
release has been shown in the rat spinal cord (Zhang et al., 1997). Our study provides 
the first evidence that PACAP-38 is released from the peripheral terminals of 
capsaicin-sensitive afferents in the rat tracheae in response to both capsaicin and 
electrical field stimulation.  
We also demonstrated that PACAP-LI can be detected in the systemic circulation of 
the rat and in vivo stimulation of capsaicin-sensitive nerves by i.v. injection of the 
ultra-potent TRPV1 receptor agonist RTX induces a two-fold elevation of basal 
plasma PACAP-38 concentration. Local electrical excitation of capsaicin-sensitive 
afferents innervating the paw skin was not sufficient to significantly increase 
PACAP-LI in the blood.  
We found that PACAP-38 is able to inhibit both chemically- and electrically-induced 
substance P, CGRP and somatostatin release from capsaicin-sensitive fibres in a 
concentration-dependent manner. The maximal inhibitory action of PACAP-38 on 
sensory neuropeptide release was 70-90% which suggests higher potency than that of 
similar concentrations of nociceptin and the heptapeptide somatostatin analogue TT-
232 (45-65% inhibition). The efficacy of PACAP is similar to the efficacy of 
nociceptin or somatostatin (Helyes et al., 1997; Helyes et al., 2001). It has previously 
been described that PACAP-38 suppressed vagal nerve stimulation-induced non-
adrenergic non-cholinergic tracheal contractions without affecting the effect of 
exogenously administered SP. The authors concluded that PACAP may inhibit SP 
release from nerve terminals (Shigyo et al., 1998), which is supported by our results. 
Interestingly, in the isolated, perfused porcine antrum PACAP-38 lead to 
somatostatin and SP release, the source of which has not been elucidated (Tornoe et 
al., 2001). These data might reveal species- and organ-dependent differences in the 
actions of PACAP.  
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Our data demonstrate that systemic administration PACAP-38 inhibits neurogenic 
inflammation in the mouse in vivo in a dose-dependent manner. Furthermore, i.p. 
PACAP-38 injection significantly diminished mustard oil-evoked plasma protein 
extravasation in the skin of the rat hindpaw. Since mustard oil-induced release of 
pro-inflammatory neuropeptides is exclusively responsible for ear swelling in this 
pure neurogenic inflammatory model, the inhibition of their outflow by PACAP-38 
results in the decrease of oedema formation. Ear sections representing the 
histopathological changes 3 h after mustard oil smearing revealed that marked 
oedema developed in the connective tissue without significant number of 
accumulated leukocytes. These findings are supported by our earlier data 
demonstrating that mustard oil-evoked neutrophil accumulation appears 6 h after 
challenge. However, capsaicin-sensitive sensory fibres are not involved in the 
cellular phase of the inflammatory reaction (Bánvölgyi et al., 2004).  
We also provided evidence for the ability of i.p. injected PACAP-38 to inhibit 
capsaicin- or RTX-induced acute neurogenic plasma protein extravasation in the 
plantar skin of the rat hindpaw. Both ligands selectively activate TRPV1 receptors on 
capsaicin-sensitive nerves, but RTX has a thousand-fold greater potency (Szállási & 
Blumberg, 1989; Lazar et al., 2006). Our results also showed that thousand times 
smaller concentration of RTX induced similar Evans blue leakage to capsaicin.  
PACAP also decreased carrageenan-induced inflammation, in which both neurogenic 
and non-neurogenic components are involved (Romero et al., 2005). Several cellular 
and neural mediators, such as bradykinin and tachykinins, are implicated in the 
exsudative response evoked by carrageenan, but complement factors and histamine 
seem to have minor roles (Dawson et al., 1991; Romero et al., 2005). Concerning the 
involvement of capsaicin-sensitive fibres is not completely consistent. Sensory 
neurogenic components have been shown to play a pivotal role in carrageenan-
evoked joint (Lam & Ferrell, 1989) and pleural inflammation (Raychaudhuri et al., 
1991), as well as in cutaneous neutrophil accumulation (Cao et al., 2000). Others 
found that capsaicin-sensitive sensory fibres are not important in carrageenan-
induced plasma extravasation and oedema in the skin (Zhou et al., 1998), but the 
integrity of sympathetic fibres is required (Coderre et al., 1989).  
The anti-inflammatory effect of PACAP-38 in these different models is likely to be 
explained by its ability to diminish the release of SP and CGRP from sensory nerves, 
as well as other inflammatory mediators from sympathetic fibres or cellular sources. 
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Besides these pre-junctional actions, its direct inhibitory effect on plasma 
extravasation and oedema formation at the level of the vascular endothelium can also 
be assumed. This possibility is supported by the presence of PAC1 receptors on 
endothelial cells (Abu-Hamdan et al., 2006) and the direct anti-apoptotic effects 
observed in these cell cultures after PACAP administration (Rácz et al., 2007). 
Numerous data indicate the localization of PACAP and its receptors on blood vessels 
and its relaxing action on vascular smooth muscle (Fahrenkrug et al., 2000; 
Dalsgaard et al., 2003), but this vasodilatory effect has been shown to be independent 
of the endothelium (Warren et al., 1991).  
PACAP-38 functions as an immunomodulator, and the majority of the studies report 
on its anti-inflammatory actions (Ganea & Delgado, 2002; Abad et al., 2006). 
Intraperitoneal administration of PACAP-38 in mice has been shown to reduce 
inflammatory changes in the collagen-induced arthritis model by modulating several 
inflammatory soluble factors (Abad et al., 2001) and to ameliorate the clinical 
manifestations of experimental autoimmune encephalomyelitis by suppressing the 
function of antigen presenting cells (Kato et al., 2004). Clinical studies have also 
suggested that PACAP is involved in inflammatory processes in psoriasis (Steinhoff 
et al., 1999). However, there are also data on its pro-inflammatory actions, like 
vasodilation and oedema formation in the rabbit eye (Wang et al., 1995; Wang et al., 
1997). Furthermore, intradermal injections of low PACAP-38 concentrations evoked 
plasma extravasation in the rat and rabbit skin by inducing histamine release from 
activated mast cells and directly dilating blood vessels (Warren et al., 1993; Cardell 
et al., 1997). Based on these data it seems that the effects of PACAP-38 depends on 
its route of administration (central versus peripheral) as well as the pathological 
mechanisms of the inflammatory models used.  
In summary, we provided clear evidence that PACAP-38 is released from the 
stimulated peripheral terminals of capsaicin-sensitive afferents. Furthermore, we 
described a specific and sensitive radioimmunoassay technique for reliable 
determination of PACAP-LI in the rat plasma. With the help of this method we 
showed that PACAP-38 is released from capsaicin-sensitive afferents into the 
systemic circulation via TRPV1 receptor. We proved that PACAP-38 is able to 
inhibit the outflow of neuropeptides from sensory fibres. Based on this mechanism of 
action it is also able to effectively diminish neurogenic inflammatory response in 
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vivo after systemic administration. We also show the ability of systemically 
administered PACAP-38 to inhibit mixed-type oedema formation in the rat paw.  
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Systemic sensitizing effect of non-neurogenic inflammation 
on capsaicin-sensitive afferents in the mouse ear 
 
 
Introduction 
 
Phorbol 12-myristate 13-acetate (PMA)-induced mouse ear inflammation has been 
commonly used as a model to study the effect of anti-inflammatory agents (Young et 
al., 1983; Carlson et al., 1985; De Young et al., 1989; Kuchera et al., 1993; Garrido 
et al., 2004; Huang et al., 2006). In these reports ear swelling, neutrophil infiltration, 
histopathological changes and local cytokine concentration were the indicators of 
inflammatory processes. PMA, when administered topically to the mouse ear, 
induces a pronounced inflammatory response mediated by protein kinase C (PKC) 
(Kuchera et al., 1993). Neurogenic components were also evidenced in PMA-
induced inflammation in murine ears by vanilloid-pre-treated animals. PMA induced 
early oedema response in the mouse ear was strongly inhibited by pre-treatment with 
RTX (Szállási & Blumberg, 1989).  
Phosphorylation and consequent sensitization/activation of TRPV1 receptors by PKC 
has been established by numerous studies (Cesare et al., 1999; Chuang et al., 2001; 
Varga et al., 2006).  
The aim of the present work was to investigate the role of capsaicin-sensitive sensory 
nerve endings and TRPV1 receptors in the nerve-sensitizing effect of PMA-induced 
ear inflammation.  
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Methods 
 
 
Animals 
 
Experiments were performed on male C57BL/6 TRPV1 receptor gene knockout mice 
(TRPV1-/-) and their wild-type counterparts (TRPV1+/+). The ancestors of the 
transgenic mice were donated by Dr. J. B. Davis, Neurology and GI Centre of 
Excellence for Drug Discovery, GlaxoSmithKline, Research and Development Ltd., 
New Frontiers Science Park, Essex, Harlow, UK (Davis et al., 2000). TRPV1 
knockout mice were fully backcrossed into C57BL/6 mice and these animals were 
used to generate TRPV1 knockout colonies. TRPV1-/- animals showed normal 
growth and behavioural characteristics. Animals were bred in the Animal House of 
Pécs University under pathogen free condition at 24-25 ºC in climatically controlled 
environment, given standard diet and water ad libitum.  
 
 
PMA and acetone treatment 
 
TRPV1 receptor knockout and wild-type mice were anaesthetized by ketamine (100 
mg/kg i.p., repeated if necessary) and xylazine (5 mg/kg i.p.). Right ears of the 
animals were smeared with PMA dissolved in acetone. PMA (1.25 g) was applied 
in 10-10 l volume to the inner and outer surfaces of the right ear. Left ears were 
smeared with 10-10 l acetone. Separate groups of animals received acetone on both 
ears or PMA on the right ear and the left ear remained untreated. At the end of the 
incubation period animals were killed by cervical dislocation, ears were dissected for 
histology and myeloperoxidase assay.  
 
 
Systemic resiniferatoxin pre-treatment 
 
Neuropeptides from capsaicin-sensitive primary afferents were depleted by systemic 
resiniferatoxin treatment. RTX stock solution (1 mg/ml) was dissolved in 96% 
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ethanol, further dilutions were produced by saline. Anaesthetized TRPV1+/+ animals 
received 10, 30 and 100 g/kg RTX s.c. into the neck region on three consecutive 
days. Mice received aminophylline (1.92 mg/kg), terbutaline (20 g/kg) and atropine 
(20 g/kg) i.p. just before RTX treatment to avoid respiratory complications. 
Experiments were carried out 14 days after RTX pre-treatment. The effect of pre-
treatment was checked by the eye wiping test. Desensitization was declared 
successful, if 0.1% capsaicin dropped into the eye did not cause wiping movements.  
 
 
Local capsaicin treatment 
 
Right or left ears of TRPV1+/+ animals were treated with 0.5% capsaicin dissolved 
in 70% ethanol. Contralateral ears were smeared with ethanol. Capsaicin treatment 
was performed 5 times in every second hour and this procedure was repeated on the 
consecutive day. Animals were recruited to the experiment after 4 days (Gábor & 
Rázga, 1992). In a group PMA was applied on the right, capsaicin-treated ear, and 
the left ear received acetone. In another animal group acetone treatment was 
performed on the left, capsaicin-treated side and PMA was used on the right, ethanol 
treated ear.  
 
 
Ibuprofen treatment 
 
In a separate group of wild-type mice, 70 mg/kg ibuprofen sodium dissolved in 
saline was injected i.p. 45 min before the PMA-acetone treatment and this procedure 
was repeated in the 6
th
 and 12
th
 hours.  
 
 
Anti-IL-1  antibody treatment 
 
Five g of polyclonal goat anti-mouse IL-1  IgG was administered i.v. to a group of 
mice. Normal goat IgG was used as control. An hour after the injection animals 
received PMA-acetone treatment and ear thickness was checked as discussed below.  
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Measurement of ear oedema 
 
Ear thickness was measured before smearing with either acetone (left ears or both 
ears in a separate group of animals) or PMA (right ears) and after the treatments in 
different time points as described previously. We used an engineers’ micrometer 
(0.01 mm accuracy). Data were expressed as % increase of ear thickness compared to 
the initial pre-challenge values.  
 
 
Myeloperoxidase assay 
 
Myeloperoxidase activity correlates to the number of accumulated neutrophils. 
Samples were collected 12 hours after acetone and PMA challenge and stored at -20 
ºC. Ears were weighed, chopped into small pieces and homogenised in phosphate 
buffer containing 0.5% hexadecyltrimethylammonium bromide. Two ml buffer was 
used for each ear. The homogenate was centrifuged at 10000 g, 4 ºC for 10 minutes 
and 500 l of the supernatant was collected. Myeloperoxidase activity was 
determined in 96 well microtitre plates using 3, 3’, 5, 5’-tetramethyl-benzidine at 
room temperature. The optical density (OD) at 620 nm was measured at 5 min 
intervals using a microplate reader. The reaction rate was calculated and a calibration 
curve was produced with the reaction rate plotted against MPO content using 
standard samples (MPO from human leukocytes).  
 
 
Histology 
 
Samples were fixed in 4% buffered paraformaldehyde and embedded into paraffin. 5 
m cross sections were made and stained with haematoxylin and eosin. Digital 
photographs were taken of the slides by an Olympus BX51 microscope and Olympus 
DP50 camera. To reflect the severity of inflammation, the extent of the oedema, 
formation of microabscesses after necrosis of hair follicles and sebaceous glands and 
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number of accumulated mononuclear and polymorphonuclear cells were scored. 
Composite scores for the different experimental groups were calculated.  
 
 
Measurement of IL-1  concentration 
 
Samples were weighed, put into RPMI medium containing phenylmethylsulfonyl 
fluoride (1 ml each) and chopped into small pieces. Ears were homogenized and 
centrifuged at 10000 g, 4 ºC for 10 minutes and 500 l of supernatants were 
collected. IL-1  content was determined by BD OptEIA ELISA set.  
 
 
Statistics 
 
Results are expressed as mean ± standard error of mean (SEM). Comparisons 
between different groups of animals were performed by ANOVA followed by 
Bonferroni’s test. Probability values p<0.05 were accepted as significant.  
 
 
Ethics 
 
Ethical guidelines declared in the previous chapter were observed when executing 
the present studies.  
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Results 
 
 
Effect of genetic lack of TRPV1 receptor, systemic RTX pre-treatment, local 
capsaicin desensitization and ibuprofen treatment on PMA- and acetone-
induced ear oedema 
 
If the right ears were treated with PMA, acetone treated left ears produced 
approximately 85% increase of thickness within 12 hours both in TRPV1+/+ and -/- 
animals. This decreased to approximately 46-62% at 24 hours. In the first 4 hours 
these acetone treated ears did not show detectable swelling. Initial ear thickness 
values of TRPV1+/+ and -/- animals were 272.96±2.66 m and 266.52±4.89 m 
respectively for the acetone treated left ears (Fig. 10). PMA induced 163-196% ear 
swelling both in TRPV1+/+ and TRPV1-/- mice during the 24 hour measurement 
period compared to the pre-stimulated baseline thickness. Pre-stimulated ear 
thickness values of the PMA-treated right ears were 276.67±2.72 m for TRPV1+/+ 
and 270.00±4.12 m for TRPV1-/- mice (Fig. 10).  
Systemic pre-treatment of TRPV1+/+ animals with the ultra-potent capsaicin 
analogue resiniferatoxin ameliorated contralateral acetone-induced ear swelling at 
every time point (0-24 h) compared to TRPV1+/+ mice. Oedema was reduced by 33-
83%. Baseline ear thickness values of the left, acetone-treated ears were 254.62±2.43 
m (Fig. 11). PMA-induced ear oedema formation was inhibited by 30-50% 
particularly in the early phase (0-6 h) of inflammation. Initial values of the right, 
PMA-treated ears were 247.77±3.95 m (Fig. 11).  
Only 12-20% increase in ear oedema was observed in a separate group of mice 
wherein both ears were treated with acetone (Fig. 10). Interestingly, if the left ear 
was not treated with acetone, PMA treatment on the right side induced about 30% 
increase in ear thickness on the untreated left side both in TRPV1 receptor knockout 
and wild type mice (data are not shown).  
Neither genetic lack of TRPV1 receptors nor systemic RTX pre-treatment produced 
significant changes in bilateral acetone treatment-induced ear oedema. Baseline 
values were 317.78±5.21 m, 375.42±1.20 m and 297.50±5.041 m for 
TRPV1+/+, -/- and TRPV1+/+ RTX-pre-treated mice, respectively (Fig. 11).  
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In a separate animal group local capsaicin-desensitization was performed on the 
acetone treated left side, but not on the PMA treated right ear of TRPV1+/+ mice. In 
spite of strong inflammatory changes at the PMA-treated side, acetone evoked only 
moderate ear swelling. Initial value of the pre-treated left ears was 303.33±4.94 m 
and of the PMA-treated right ears was 303.33±1.20 m. Baseline values of the 
control acetone (left) and PMA-treated (right) ears were 295.00±6.45 m and 
320.00±16.83 m, respectively (Fig. 12a). If local capsaicin desensitization was 
fulfilled on the right, PMA-treated ear, PMA-evoked early ear oedema was inhibited. 
Contralateral acetone treatment on the non-desensitized left ear induced 
approximately 74-91% ear swelling. Baseline values of the acetone treated and the 
capsaicin-PMA treated ears were 303.33±4.94 m and 290.00±4.47 m. Initial 
values of control acetone (left) and PMA-treated (right) ears were 286.67±11.16 m 
and 278.33±4.77 m (Fig. 12b). 
Treatment of TRPV1+/+ mice with ibuprofen (70 mg/kg), a cyclooxygenase 
inhibitor, completely prevented ear swelling induced by contralateral acetone 
application on the left (Fig. 13). Ibuprofen treatment did not cause significant change 
in PMA-oedema on the right. Initial values of the ibuprofen-treated acetone- and 
PMA-smeared ears were 320.00±13.17 m and 321.67±13.27 m. Baseline control 
acetone (left) and PMA-treated (right) values were 300.00±5.77 m and 
290.00±11.55 m.  
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Figure 10. Contralateral 
acetone and bilateral 
acetone treatment in 
TRPV1+/+ and -/- mice. 
Measurements were 
performed before 
challenge and 0.5, 1, 2, 
4, 6, 12, 24 hours after 
it. Data are expressed as 
% change from pre-
stimulated values. 
Comparisons between 
different treatments 
were made by ANOVA 
followed by 
Bonferroni’s test. 
Values are means±SEM, 
n=6-27. *P<0.05, 
***P<0.001 vs. 
contralateral acetone in 
TRPV1+/+ animals. 
†††P<0.001 vs. 
contralateral acetone in 
TRPV1-/- animals. 
#P<0.05, ###P<0.001 
vs. bilateral acetone in 
TRPV1+/+ animals. 
xP<0.05, xxxP<0.001 
vs. bilateral acetone in 
TRPV1-/- animals.  
 
Figure 11. PMA, 
contralateral acetone 
and bilateral acetone 
treatment induced ear 
swelling in TRPV1+/+ 
RTX-pre-treated and 
control animals. 
Measurements were 
performed before 
challenge and 0.5, 1, 2, 
4, 6, 12, 24 hours after 
it. Data are expressed as 
% change from pre-
stimulated values. 
Comparisons between 
different groups were 
made by ANOVA 
followed by 
Bonferroni’s test. 
Values are means±SEM, 
n=6-27. **P<0.01, 
***P<0.001 vs. 
contralateral acetone in 
TRPV1+/+ animals. 
††P<0.01, †††P<0.001 
vs. PMA in TRPV1+/+ 
animals.  
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Effect of the lack of TRPV1 receptor and RTX pre-treatment on 
myeloperoxidase activity of ear samples 
 
Contralateral acetone treatment of the left ears induced moderate but significant 
increase in myeloperoxidase activity in TRPV1 knockout mice compared to naïve 
controls. Contralateral acetone treatment did not cause significant neutrophil 
accumulation in TRPV1+/+ and RTX-pre-treated mice (Fig. 14).  
Strongly significant increase in MPO activity was observed in PMA-challenged right 
ears after 12 hours indicating a marked increase in the accumulation of 
polymorphonuclear leukocytes and other myeloperoxidase positive cells. Neither 
systemic RTX pre-treatment, nor deletion of TRPV1 receptors caused significant 
inhibition in MPO activity compared to their controls (Fig. 14).  
 
 
Histological findings 
 
The diameter of the ear sections determined by analysis of the histological slides 
correlated with the ear thickness data. The highest number of microabscesses due to 
inflammation/necrosis of hair follicles and sebaceous glands were counted in the ears 
of TRPV1 receptor knockout animals. Contralateral acetone treatment of the left ears 
was able to induce moderate microabscess formation in knockout animals, but not in 
wild-type ones. PMA treatment of the right ears led to a pronounced increase of 
mononuclear and polymorphonuclear cells both in TRPV1+/+, TRPV1-/- and RTX-
pre-treated wild-type mice. Bilateral acetone smearing did not cause significant cell 
accumulation. Representative light micrographs demonstrate most prominent 
histopathological changes (Fig. 15).  
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Figure 12. Effect of local capsaicin desensitization on PMA (right) and contralateral acetone (left) 
induced ear oedema. (a) Capsaicin desensitization of the left, acetone-treated ear. (b) Capsaicin 
desensitization of the right, PMA-treated ear. Ear thickness measurements were performed before 
challenge and 0.5, 1, 2, 4, 6, 12, 24 hours after challenge. Data are expressed as % change from pre-
stimulated values. Comparisons between different treatments were made by ANOVA followed by 
Bonferroni’s test. Values are means±SEM, n=3-6. *P<0.05, **P<0.01 vs. TRPV1+/+ control animals 
that received contralateral acetone (left side) treatment. †P<0.05 vs. TRPV1+/+ control animals 
treated with PMA (right side).  
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Figure 13. PMA (right) 
and contralateral 
acetone (left) induced 
ear swelling in 
TRPV1+/+ ibuprofen 
treated and control 
animals. Ear thickness 
measurements were 
performed before 
challenge and 0.5, 1, 2, 
4, 6, 12, 24 hours after 
challenge. Data are 
expressed as % change 
from pre-stimulated 
values. Comparisons 
between different 
groups were made by 
ANOVA followed by 
Bonferroni’s test. 
Values are means±SEM, 
n=3-6. *P<0.05, 
**P<0.01, ***P<0.001 
vs. contralateral acetone 
(left) and saline-treated 
TRPV1+/+ animals.  
 
 
 
 
 
 
 
 
Figure 14. PMA (right 
ears) and contralateral 
acetone (left ears) 
treatment induced 
neutrophil accumulation 
in TRPV1+/+, TRPV1-
/- and TRPV1+/+ RTX-
pre-treated animals. 
Measurements were 
performed 12 hours 
after challenge. Data are 
expressed as MPO 
content per ear. 
Statistical evaluation 
was performed by 
ANOVA followed by 
Bonferroni’s test. 
Values are means±SEM, 
n=6-8. ***P<0.001 vs. 
contralateral acetone 
(left). ††P<0.01 vs. 
intact.  
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Effect of PMA and acetone treatment on local IL-1 content of the mouse ear 
 
Increased IL-1 level was measured on the acetone treated left side in PMA-treated 
(right ears) animals. Bilateral acetone treatment did not cause IL-1  elevation 
compared to the naïve controls, either in the ears of TRPV1+/+ or TRPV1-/- animals 
(Fig. 16). Furthermore, PMA treatment on the right side resulted in similarly elevated 
local IL-1  levels in the ears of TRPV1+/+ and TRPV1-/- mice (Fig. 16).  
 
 
Effect of systemic anti-IL-1  antibody treatment on PMA- and acetone-induced 
ear oedema 
 
Pre-treatment with anti-IL-1  antibody did not ameliorate the potentiating effect of 
PMA on contralateral (left side) acetone-induced ear swelling at any time points 
compared to the goat IgG-treated control. The antibody treatment also did not 
diminish PMA-induced right ear inflammation. 
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Figure 15. Representative light micrographs (100 X). (a) Bilateral acetone, (b) contralateral acetone 
(left ear) and (c) PMA (right ear) treatment in TRPV1
+/+
 animal. (d) Bilateral acetone, (e) contralateral 
acetone (left ear) and (f) PMA (right ear) treatment in TRPV1
-/-
 subject. (g) Contralateral acetone (left 
ear) and (h) PMA (right ear) application in TRPV1
+/+
 RTX-pre-treated animal.  
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Figure 16. IL-1  
content of PMA (right), 
contralateral acetone 
(left) and bilateral 
acetone-treated mouse 
ears. IL-1  detection 
was performed 12 hours 
after challenge. Data are 
expressed as pg IL-1  
per grams of ear 
samples. Comparisons 
between different 
groups were made by 
ANOVA followed by 
Bonferroni’s test. 
Values are means±SEM, 
n=6-19. ***P<0.001 vs. 
contralateral acetone 
(left) treatment. 
†P<0.05, ††P<0.01 vs. 
bilateral acetone 
application.  
 
Figure 17. Proposed 
mechanism of 
sensitization exerted by 
PMA on the capsaicin-
sensitive nerve 
terminals of the 
contralateral ear. PMA 
stimulates capsaicin-
sensitive nerve 
terminals resulting in 
neuropeptide release 
and neurogenic oedema 
in the right ear. It also 
induces the 
accumulation of 
inflammatory cells 
secreting different 
inflammatory mediators 
(kinins, cytokines) 
which enter the 
circulation and reach the 
contralateral left ear 
wherein they trigger 
prostanoid synthesis. 
Prostanoids may 
sensitize capsaicin-
sensitive fibres to 
acetone. Concurrent 
acetone application to 
the site of sensitization 
leads to neurogenic 
oedema.  
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Discussion 
 
Acetone is widely used as an inert solvent of PMA (Young et al., 1983; De Young et 
al., 1989; Szállási & Blumberg, 1989; Bermejo et al., 1998; Griswold et al., 1998; 
Garrido et al., 2004), but in our study contralaterally applied acetone revealed 
inflammatory potential after 4 hours. It increased ear thickness by 85%, but only 
when the ipsilateral ear was treated with PMA. Acetone treatment had only slight 
effect without application of PMA to the other ear. Furthermore, the intact ear 
contralateral to PMA showed significantly less swelling indicating that sensitization 
by distant PMA application is needed to provoke marked acetone-induced ear 
oedema (Fig. 17). Since oedema formation was not altered in TRPV1 gene-deleted 
mice, but significantly reduced by RTX pre-treatment and local capsaicin 
desensitization of the acetone-treated ear, we suppose that acetone acts on the 
capsaicin-sensitive nerve endings a TRPV1-independent manner. Capsaicin pre-
treatment of the PMA-treated ear did not ameliorate contra lateral acetone-induced 
ear swelling and inhibited PMA-evoked ear inflammation only at an early time point. 
These data together with the finding that contralateral acetone treatment causes 
oedema after 3-4 hours suggest that the sensitizing effect of PMA is mediated by 
substances from inflammatory cells accumulating at the PMA-treated side and not by 
capsaicin-sensitive afferents of this ear. It is possible that mediators released from the 
accumulated inflammatory cells reach the other ear via the circulation and sensitize 
capsaicin-sensitive nerve terminals.  
The fact that PMA-induced ear inflammation develops in TRPV1 knockout animals 
similarly to wild type mice underlines that phosphorylation and sensitization of 
TRPV1 receptor by PKC is not pivotal in this case. On the other hand, according to 
the present and earlier studies (Szállási & Blumberg, 1989) systemic pre-treatment 
with RTX inhibited PMA ear oedema during the first 4 hour period. Local 
desensitization with capsaicin also inhibited this early phase of PMA-induced ear 
inflammation. Since the late PMA-oedema and cellular infiltration were not affected 
by RTX or capsaicin pre-treatment, neurogenic mediation cannot be supposed.  
Together with similar findings on nociception (Ferreira et al., 1988; Follenfant et al., 
1989), previous data indicate that interleukin-1 beta sensitizes afferent nerve fibres to 
both chemical and mechanical noxious stimuli (Herbert et al., 1995). Although local 
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IL-1  concentration was increased in the acetone-treated ear, anti-IL-1  antibody 
did not attenuate contralateral acetone-evoked ear swelling. These data provide 
evidence that IL-1  from the PMA-treated ear and the locally released cytokine on 
the acetone-treated side do not play pivotal role in the potentiating effect on nerve 
endings. Since the administration of the antibody also did not influence PMA-
induced ear swelling, we conclude that IL-1  is not essential in this inflammatory 
model.  
The attenuating effect of the cyclooxygenase inhibitor ibuprofen on contralateral 
acetone-evoked ear swelling confirms that prostanoids play a pivotal role in this 
phenomenon. Ibuprofen treatment did not diminish PMA-oedema. It was described 
earlier that this cyclooxygenase inhibitor is more potent against cellular events of 
PMA-inflammation, than against oedema formation (De Young et al., 1989).  
We demonstrated the potentiating action of PMA on contralateral acetone-induced 
ear oedema and suppose the important role of prostanoids in this process. According 
to our data, IL-1  is not essential in this case of sensitization. Our results prove that 
the potentiating effect is mediated via capsaicin-sensitive nerve fibres of the acetone-
treated ear, but not via TRPV1 receptor. Furthermore we provided evidence that the 
neurogenic component of PMA-induced ear inflammation is independent of TRPV1 
receptor and IL-1  does not mediate this inflammatory process. Our data reveal that 
acetone cannot be used as an inert solvent of PMA in internally-controlled in vivo 
inflammatory animal studies. Our study sheds light on a systemic effect of non-
neurogenic mediators released from a local cellular inflammatory response which 
enhances neurogenic inflammation in distant parts of the body.  
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Role of capsaicin-sensitive afferents in dextran sulphate 
sodium-induced colonic inflammation 
 
 
Introduction 
 
TRPV1 expressing afferent nerves in the gastrointestinal tract were described by 
some authors among extrinsic sensory neurons only in rodents (Patterson et al., 2003; 
Ward et al., 2003). Others found TRPV1-like immunoreactivity in intrinsic enteric 
neurons of the guinea pig, pig and humans (Poonyachoti et al., 2002; Anavi-Goffer 
& Coutts, 2003; Chan et al., 2003). Under physiological conditions TRPV1 
expressing afferents play an important role in the regulation of gastrointestinal 
circulation, secretion, mucosal homeostasis, motility and nociception (Holzer & 
Barthó, 1996; Holzer & Maggi, 1998). Involvement of capsaicin-sensitive nerve 
endings and TRPV1 receptor in inflammatory bowel disease was also investigated. 
The two most studied animal models of ulcerative colitis and Crohn’s disease are 
oral dextran sulphate sodium (DSS)- and topical trinitrobenzene sulphonic acid 
(TNBS)-induced colonic inflammation, respectively (Okayasu et al., 1990; Morris et 
al., 1989). Pathogenetic basis of dextran sulphate-induced colitis is progressive crypt 
loss in the colonic mucosa (Cooper et al., 1993) and alterations of luminal bacterium 
species. Activation of inflammatory cells may also contribute (Verdu et al., 2000; 
Rath et al., 2001; Setoyama et al., 2003; Rachmilewitz et al., 2004). TNBS induces 
colitis by working as a hapten (Cavani et al., 1995; Neurath et al., 1995).  
Topical co-administration of 640 mol/l capsaicin inhibited TNBS-induced 
inflammation in rats (Goso et al., 1993) showing the anti-ulcerative properties of 
neuropeptides released by capsaicin from sensory fibres. Orally administered 
capsaicin was also protective against oral dextran sulphate sodium-induced colitis in 
rats (Okayama et al., 2004). In contrast with these findings some publications 
presented evidence that different TRPV1 receptor antagonists exert inhibitory action 
on TNBS- and DSS-evoked colitis in rodents (Kihara et al., 2003; Fujino et al., 2004; 
Kimball et al., 2004). Desensitization of sensory nerve ending by capsaicin pre-
treatment exacerbated inflammatory changes in TNBS, DSS and various other 
models (Leung, 1992; Reinshagen et al., 1994, 1996; Eliakim et al., 1995; 
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McCafferty et al., 1997; Barada et al., 2001; Okayama et al., 2004), but data are also 
available that neonatal capsaicin desensitization attenuates DSS colitis in rats (Kihara 
et al., 2003).  
Since experimental data concerning the role of capsaicin-sensitive sensory fibres and 
especially the TRPV1 receptor are strongly contradictory, the aim of the present 
study was to investigate the participation of sensory neurogenic components in DSS-
induced colitis. For the experiments TRPV1 receptor gene knockout mice or 
systemic pre-treatment with a higly potent capsaicin analogue, resiniferatoxin, were 
used. 
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Methods 
 
 
Animals 
 
Experiments were executed on male C57BL/6 TRPV1 receptor gene knockout mice 
(TRPV1-/-) and their wild-type counterparts (TRPV1+/+). TRPV1-/- animals were 
purchased from The Jackson Laboratory, USA. TRPV1 knockout mice were fully 
backcrossed into C57BL/6 mice and these animals were used to generate TRPV1 
knockout colonies. TRPV1-/- animals showed normal growth and behavioural 
characteristics. All animals were bred in the Animal House of Pécs University under 
pathogen free condition at 24-25 ºC in climatically controlled environment, given 
standard diet and water ad libitum.  
 
 
Induction of colitis 
 
DSS (2%) dissolved in millipore water was administered orally to mice ad libitum 
for 6 or 5 days. The standard regimen of 5% DSS for 7 days was reduced, because of 
the experienced excessive animal loss. Control animals received millipore water for 
6 days. Animals were weighed, stool consistency, and blood content were scored 
daily. After 6 days animals were anaesthetized in saturated diethyl aether vapour and 
killed by decapitation. Colons were removed and gently flushed with Krebs-
Henseleit solution to remove faeces. Colons were cut into three equal segments 
(proximal, intermediate and distal). Four mm wide rings were obtained from each 
colon segment and put into 4% buffered paraformaldehyde for histological 
examination. The remaining samples were put on -20 °C for myeloperoxidase assay.  
 
 
Systemic resiniferatoxin pre-treatment 
 
Systemic RTX pre-treatment was performed and validated as described previously.  
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Disease activity index 
 
Weight loss compared to initial body weight, stool consistency and blood content of 
stool were scored daily as described previously (Stevceva et al., 2001). Each 
parameter was given a score ranging from 0 to 4. Disease activity index is the mean 
of weight loss, stool consistency and stool blood content scores. Occult rectal 
bleeding was detected by a commercial test using modified guaiac-method. Survival 
analysis of TRPV1+/+, TRPV1-/- and TRPV1+/+ RTX-pre-treated DSS drinking 
animals was also performed.  
 
 
Myeloperoxidase assay 
 
Samples were stored at -20 ºC. Colon segments were weighed, chopped into small 
pieces and homogenised in 1 ml of 50 mM potassium phosphate buffer containing 
0.5% hexadecyltrimethylammonium bromide (pH 6). The homogenate was 
centrifuged at 10000 g, 4 ºC for 10 minutes. 400 l of the supernatant was collected. 
Myeloperoxidase activity was determined as described above.  
 
 
Histology 
 
Four mm wide rings from proximal, intermediate and distal colon segments were 
fixed in 4% buffered paraformaldehyde and embedded into paraffin. 5 m cross 
sections were made and stained with haematoxylin and eosin. Digital micrographs 
were taken by an Olympus BX51 microscope and Olympus DP50 camera. Crypt 
height, severity and extent of inflammation were scored as described earlier (Mantyh 
et al., 1996; Tessner et al., 1998; Kihara et al., 2003). Histological evaluation was 
performed by AnalySIS software (Soft Imaging System).  
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Statistics 
 
Results are expressed as mean ± standard error of mean (SEM). Statistical evaluation 
of data was fulfilled with Student’s t-test and ANOVA followed by Bonferroni’s test. 
Survival analysis was performed by logrank test. Probability values p<0.05 were 
accepted as significant.  
 
 
Ethics 
 
Ethical guidelines proclaimed previously were observed when performing these 
studies.  
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Results 
 
 
Disease activity index 
 
By the end of the 6 day regimen severe bloody diarrhoea was developed in each 
TRPV1+/+ animal. Two percent DSS solution led to death of 57.14% of animals in 
this strain. Genetic lack of TRPV1 receptor did not affect the disease activity index 
(Fig. 18a). All TRPV1-/- mice showed also bloody diarrhoea and 38.46% of them 
died in 6 days. At the RTX-pre-treated TRPV1+/+ animal group the regimen had to 
be reduced to 5 days, because of enormous loss of animals (91.67%). Surprisingly, 
nevertheless the striking sudden loss of animals on the 6
th
 day, systemic RTX pre-
treatment did not change disease activity index values compared to TRPV1+/+ mice 
(Fig. 18a). Survival curve of TRPV1+/+ RTX-pre-treated DSS drinking animals 
showed significant lower survival probability compared to TRPV1+/+ DSS-treated 
mice (Fig. 18b).  
 
 
Myeloperoxidase activity of colon samples 
 
Myeloperoxidase (MPO) activity values of proximal, intermediate and distal colon 
segments were measured separately. DSS treatment induced significant elevation of 
MPO level in all experimental groups compared to solvent drinking control (Fig. 
19a, b, c). TRPV1 knockout animals showed more than two-fold increase of MPO 
activity compared to TRPV1+/+ mice in the intermediate colon segment (Fig. 19b). 
In intermediate and distal colon segments functional block of capsaicin-sensitive 
afferent fibres by systemic RTX pre-treatment led to significantly higher MPO 
activity values compared to TRPV1+/+ animals (Fig. 19b, c).  
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Figure 18. (a) Effect of 2% dextran sulphate sodium in drinking water for 6 days on disease activity 
index of TRPV1+/+, TRPV1-/- and TRPV1+/+ RTX-pre-treated mice. Body weight loss, stool 
consistency, stool blood content were scored and disease activity index was calculated daily. 
Comparisons between different groups were made by unpaired t test. Values are means±SEM, n=6-
14. (b) Survival curves of dextran sulphate sodium-treated TRPV1+/+, TRPV1-/- and TRPV1+/+ 
RTX-pre-treated animals. Comparisons between different groups were made by logrank test. Values 
are means±SEM, n=12-14. *P<0.05 vs. TRPV1+/+ mice.  
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Figure 19. Effect of 2% dextran sulphate sodium (DSS) on neutrophil accumulation in the colon of 
TRPV1+/+, TRPV1-/- and TRPV1+/+ RTX-pre-treated animals. Measurements were performed after 
consumption of DSS in drinking water for 6 days (5 days by TRPV1+/+ RTX-pre-treated mice). 
Myeloperoxidase enzyme (MPO) activity of (a) proximal, (b) intermediate and (c) distal colon 
segments was determined separately. Data are expressed as MPO content per g wet tissue. Statistical 
evaluation was performed by unpaired t test. Values are means±SEM, n=6-8. *P<0.05, **P<0.01 vs. 
distilled water. +P<0.05, ++P<0.01 vs. DSS treated TRPV1+/+ animals.  
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Histology 
 
Composite histological scores of dextran sulphate sodium-treated animals were 
significantly higher than those of water-treated ones in all colon segments and all 
animal groups (Fig. 20a, b, c). Genetic lack of the TRPV1 receptor induced 
significantly more enhanced histological changes compared to wild-type mice in the 
intermediate and distal colon segments (Fig. 20b, c). RTX pre-treatment, which 
depletes sensory neuropeptide content of capsaicin-sensitive nerve endings, resulted 
in significantly more pronounced inflammatory processes compared to TRPV1+/+ 
mice (Fig. 20b, c). Representative light micrographs illustrate histopathological 
features (Fig. 21).  
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Figure 20. Histological changes in the colons of TRPV1+/+, TRPV1-/- and TRPV1+/+ RTX-pre-
treated mice after drinking 2% dextran sulphate sodium (DSS) in water for 6 or 5 (TRPV1+/+ RTX-
pre-treated animals) days. Severity of cell accumulation, extent of inflammation, degree of crypt 
damage was scored and composite histological score was calculated. Histological features of (a) 
proximal, (b) intermediate and (c) distal colon segments were evaluated separately. Statistical 
evaluation was performed by ANOVA followed by Bonferroni’s test. Values are means±SEM, n=6-8. 
**P<0.01, ***P<0.001 vs. water drinking control. +P<0.05, ++P<0.01 vs. DSS-treated TRPV1+/+ 
mice.  
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Figure 21. Representative light micrographs (100 X). Intermediate colon segment of water (a) and 2% 
dextran sulphate sodium (DSS) (b) treated TRPV1+/+ animal; water (c) and 2% DSS (d) treated 
TRPV1-/- animal; water (e) and 2% DSS (f) drinking TRPV1+/+ RTX-pre-treated animal.  
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Discussion 
 
Major findings of the present study are that genetic lack of TRPV1 receptors as well 
as desensitization of the capsaicin-sensitive sensory nerve endings aggravate 
histopathological changes and increase the number of accumulated neutrophils in 
dextran sulphate sodium-induced experimental colitis in C57BL/6 mice. These 
alterations can be observed in the intermediate and distal colon segments. 
Inflammation of the proximal segment does not show significant differences in 
TRPV1 receptor knockout or RTX-pre-treated desensitized animals compared to 
wild-type controls. The role of neurogenic modulatory component in the 
pathogenesis of inflammatory bowel diseases has been raised for more than ten years 
ago (Gross & Pothoulakis, 2007). Sensory neuropeptides, such as substance P (SP), 
corticotrophin-releasing hormone, neurotensin, vasoactive intestinal peptide, mu-
opioid receptor agonists and galanin may play a potentially key role in inflammatory 
bowel disease. Several lines of evidence implicate that elevated SP level correlates 
with disease activity in certain experimental colitis model (Reinshagen et al., 1997). 
Reinshagen and co-workers demonstrated that sensory denervation with the 
neurotoxin capsaicin worsened the inflammation in an acute and chronic model of 
experimental colitis which suggests a protective role of sensory fibres during gut 
inflammation (Reinshagen et al., 1998). They found that the CGRP antagonist 
CGRP-8-37 and immunoneutralising CGRP antibody increased the severity of 
inflammation in an immune-complex model of colitis. According to these findings 
they suggested a protective role of CGRP during chronic experimental colitis. 
Corticotropin-releasing hormone receptor 2-deficient mice showed reduced intestinal 
inflammatory responses (Kokkotou et al., 2006). Neurotensin stimulates intestinal 
wound healing following chronic inflammation (Brun et al., 2005). Antagonism of 
VIP returned jejunal fluid absorption to normal values in iodoacetamide-evoked 
colitis in rats (Mourad et al., 2006). Chronic administration of galanin attenuates 
TNBS-induced colitis in rats (Talero et al., 2007). Philippe and co-workers suggest 
beneficial effects of  opioid agonists in inflammatory bowel disease (Philippe et al., 
2006).  
Animal models of experimental ulcerative colitis are useful tools for investigating the 
pathomechanism of the disease. Dextran sulphate sodium-induced colitis shows 
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classical symptoms of ulcerative colitis, such as chronic relapsing diarrhoea, rectal 
bleeding and inflammation, mucosal ulceration and microscopic crypt abscesses. 
Ulcerated areas demonstrate markedly increased epithelial cell apoptosis and 
necrosis by histologic examination (Boismenu et al., 2002; Vetuschi et al., 2002).  
Data about the involvement of TRPV1 receptor and sensory neuropeptides in DSS 
colitis are contradictory. Kihara and Kimball found that various neuropeptides 
liberated from capsaicin-sensitive nerve endings have pro-inflammatory cumulative 
effect. They report that TRPV1 antagonists (capsazepine, JNJ 10185734) and 
functional denervation of capsaicin-sensitive fibres by neonatal capsaicin treatment 
decrease the severity of colitis in rats (Kihara et al., 2003; Kimball et al., 2004). In 
contrast with these findings, Okayama and co-workers demonstrated that orally 
administered selective TRPV1 receptor agonist capsaicin, which releases sensory 
neuropeptides, inhibited DSS-induced colitis in rats. They also established that 
capsaicin desensitization increased the inflammatory response (Okayama et al., 
2004). Their results suggest that sensory neuropeptides exert an anti-inflammatory 
cumulative effect in this model. Our findings are in keeping with those of Okayama 
and underline that desensitization of the capsaicin-sensitive sensory nerves by RTX 
or genetic deletion of TRPV1 receptor exacerbates the histopathological changes and 
decreases the survival probability in the DSS colitis. Since in vivo effectiveness of 
TRPV1 receptor antagonists is questionable, investigation on TRPV1 receptor 
knockout animals and wild-type counterparts means the most appropriate 
experimental approach.  
Conflicting results may be explained by strain and site specific susceptibility of the 
colonic mucosa. Studies show that guinea pigs and C57BL/6 mice are more 
susceptible to the inflammatory effect of DSS (Iwanaga et al., 1994; Krieglstein et 
al., 2001). In addition different species and strains show most severe inflammatory 
reactions in different segments of the colon. Swiss-Webster, CBA/j mice and Fisher 
344 rats develop left sided colitis (Okayasu et al., 1990; Cooper et al., 1993; Domek 
et al., 1995), whereas Wistar rats, hamsters and guinea pigs develop right-sided 
colitis (Yamada et al., 1992; Tamaru et al., 1993; Iwanaga et al., 1994).  
According to earlier studies disease activity index shows an excellent correlation 
with crypt architectural changes (Cooper et al., 1993). In our experiments disease 
activity index did not follow the differences of myeloperoxidase activity and 
histological changes properly. On the other hand, survival analysis proved that the 
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RTX-pre-treated animals had significantly less probability to survive the 6 days 
protocol.  
In conclusion we suggest that learning more about modulatory role of TRPV1 
receptors and capsaicin-sensitive nerve endings in the inflammatory bowel disease 
may contribute to the development of novel type anti-inflammatory drugs available 
in the therapy of ulcerative colitis.  
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Novel findings 
 
1. Our data demonstrate that PACAP-38 can be released from the sensory 
nerves of the rat trachea either by capsaicin treatment or electrical field 
stimulation. We also provide evidence that PACAP-38-like immunoreactivity 
can be detected in the naïve rat plasma. The presence of PACAP-38 in the rat 
plasma was verified by mass spectrometry using matrix-assisted laser 
desorption/ionization. The ultra-potent TRPV1 receptor agonist 
resiniferatoxin proved to be able to induce a twofold increase in the plasma 
PACAP-38 level. On the other hand, bilateral electrical stimulation of the 
sciatic nerves was incapable of evoking such an increase.  
2. Our studies evince anti-inflammatory action of PACAP-38 against both 
neurogenic and mixed type inflammatory stimuli. PACAP-38 dose 
dependently inhibited capsaicin and electrical field stimulation-evoked 
neuropeptide release in the rat trachea. Systemic applied PACAP-38 
significantly and dose dependently diminished mustard oil-induced 
neurogenic plasma extravasation in the mouse ear. PACAP-38 given 
intravenously also inhibited mustard oil-induced inflammation in the rat 
hindpaw. Neurogenic inflammation of the rat hinpaw evoked by intraplantar 
administration of capsaicin or resiniferatoxin was significantly diminished by 
systemic PACAP-38 administration. Intravenous PACAP-38 successfully 
mitigated carrageenan-induced inflammation of the rat hindpaw, which model 
involves both neurogenic and non-neurogenic inflammatory mechanisms.  
3. We observed sensitizing effect of PMA-induced inflammation on acetone-
evoked oedema in the mouse ear. These findings reveal a process where non-
neurogenic inflammatory mediators sensitize afferent neurons in distal parts 
of the body. Our data demonstrate that capsaicin-sensitive sensory nerve 
endings play a pivotal role in the mechanism of potentiation, because 
systemic resiniferatoxin pre-treatment inhibited the sensitizing effect. Using 
genetically modified animals we also proved that TRPV1 receptor is not 
essential in this phenomenon. Genetic lack of TRPV1 receptor did not 
influence sensitizing effect of PMA-induced inflammation. We found that 
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prostanoids are important mediators in the process, but IL-1  does not have 
any important action. Ibuprofen, a cyclooxygenase inhibitor, significantly 
diminished acetone-induced ear oedema which arises upon the basis of the 
potentiating effect of PMA ear inflammation. Intravenously applied anti-IL-
1  antibody did not inhibit acetone-evoked ear oedema.  
4. Our results elucidated some unclear details of the pathomechanism of PMA 
induced inflammation. We found that in contempt of heavy involvement of 
capsaicin-sensitive nerve endings in PMA-induced ear inflammation, genetic 
lack of TRPV1 receptor did not influence the condition. Our data show that 
IL1-  is not essential in mediating PMA evoked ear inflammation, because 
anti IL-1  antibody did not attenuate ear swelling in this model.  
5. Our studies demonstrated that functional ablation of capsaicin-sensitive 
afferent nerve endings and genetic lack of TRPV1 receptor exacerbate 
inflammatory cell accumulation and other histological features of dextran 
sulphate sodium-induced colitis in C57BL/6 mice.  
On the whole our results emphasize anti-inflammatory cumulative action of 
neuropeptides derived from capsaicin-sensitive nerve terminals in different animal 
models of inflammatory disease. Our data also accentuate that capsaicin-sensitive 
neurons can become targets of sensitizing effect of non-neurogenic inflammatory 
processes. Thriving knowledge about diverse role of capsaicin-sensitive afferents and 
TRPV1 receptors in inflammatory disease may promote the development of novel, 
clinically useful anti-inflammatory agents.  
 
 
 71 
Acknowledgements 
 
I would like to thank my supervisor, Erika Pintér, the vast support she provided. I 
would like to acknowledge Professor János Szolcsányi, director of the 
Neuropharmacology Program, the opportunity to participate. I would like to express 
my gratitude to Zsuzsanna Helyes, József Németh, Dóra Reglődi, Katalin Sándor, 
Anikó Perkecz, Teréz Bagoly, Rita Börzsei, Professor Loránd Barthó, Rita Benkó 
and Kata Bölcskey for theoretical and practical support. I would also like to 
acknowledge Ms. Csilla Zádor and Mrs. Mária Zöldhegyi for excellent technical 
assistance.  
 
 72 
References 
 
Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating 
polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. 
J Immunol 2001;167:3182-3189.  
Abad C, Martinez C, Leceta J, Juarranz MG, Delgado M, Gomariz RP. Pituitary adenylate-cyclase-
activating polypeptide expression in the immune system. Neuroimmunomodulation 
2002;10:177-186.  
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of 
inflammatory disease: focus on VIP and PACAP. Curr Top Med Chem 2006;6:151-163.  
Abu-Hamdan MD, Drescher MJ, Ramakrishnan NA, et al. Pituitary adenylate cyclase activating 
polypeptide (PACAP) and its receptor (PAC1-R) in the cochlea: evidence for specific 
transcript expression of PAC1-R splice variants in rat microdissected cochlear subfractions. 
Neuroscience 2006;140:147-161.  
Aliakbari J, Sreedharan SP, Turck CW, Goetzl EJ. Selective localization of vasoactive intestinal 
peptide and substance P in human eosinophils. Biochem Biophys Res Commun 
1987;148:1440-1445.  
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin 
gene expression generates mRNAs encoding different polypeptide products. Nature 
1982;298:240-244.  
Anavi-Goffer S, Coutts AA. Cellular distribution of vanilloid VR1 receptor immunoreactivity in the 
guinea-pig myenteric plexus. Eur J Pharmacol 2003; 458: 61-71.  
Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the 
neuroendocrine, endocrine, and nervous systems. Jpn J Physiol 1998;48:301-331.  
Bandari PS, Qian J, Yehia G, et al. Hematopoietic growth factor inducible neurokinin-1 type: a 
transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regul Pept 
2003;111:169-178.  
Bánvölgyi Á, Pozsgai G, Brain SD, et al. Mustard oil induces a TRPV1 receptor independent 
neurogenic inflammation and a non-neurogenic cellular inflammatory component. 
Neuroscience 2004;125:449-459.  
Barada KA, Kafrouni MI, Khoury CI, et al. Experimental colitis decreases rat jejunal amino acid 
absorption: role of capsaicin sensitive primary afferents. Life Sci 2001;69:3121-3131.  
Barnes PJ. Asthma as an axon reflex. Lancet 1986;1:242-245.  
Bartho L, Benko R, Patacchini R, et al. Effects of capsaicin on visceral smooth muscle: a valuable tool 
for sensory neurotransmitter identification. Eur J Pharmacol 2004; 500: 143-157.  
Bayliss WM. The Vaso-motor System. London: Longmans Green, 1923.  
Benham CD, Davis JB, Randall AD. Vanilloid and TRPV channels: a family of lipid-gated cation 
channels. Neuropharmacology 2002;42:873-888.  
Bermejo BP, Abad Martinez MJ, Silvan Sen AM, et al. In vivo and in vitro antiinflammatory activity 
of saikosaponins. Life Sci 1998;63:1147-1156.  
 73 
Bertrand C, Geppetti P, Baker J, Yamawaki I, Nadel JA. Role of neurogenic inflammation in antigen-
induced vascular extravasation in guinea pig trachea. J Immunol 1993;150:1479-1485.  
Bester H, Allchorne AJ, Woolf CJ. Recovery of C-fiber-induced extravasation following peripheral 
nerve injury int he rat. Exp Neurol 1998;154:628-636.  
Blumberg PM, Szállási A, Ács G. Resiniferatoxin-an ultrapotent capsaicin analogue. In: Wood JN, ed. 
Capsaicin in the Study of Pain. London: Academic Press, 1993:45-62.  
Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R. Orally administered RDP58 reduces the 
severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 2002;61(Suppl 2):ii19-
24.  
Bölcskei K, Helyes Z, Szabó Á, et al. Investigation of the role of TRPV1 receptors in acute and 
chronic nociceptive processes using gene-deficient mice. Pain 2005;117:368-376.  
Brain SD. Sensory neuropeptides: their role in inflammation and wound healing. 
Immunopharmacology 1997;37:133-152.  
Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol 
Rev 2004;84:903-934.  
Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a 
potent vasodilator. Nature 1985;313:54-56.  
Bredow S, Kacsoh B, Obal F Jr, Fang J, Krueger JM. Increase of prolactin mRNA in the rat 
hypothalamus after intracerebroventricular injection of VIP or PACAP. Brain Res 
1994;660:301-308.  
Brun P, Mastrotto C, Beggiao E, et al. Neuropeptide neurotensin stimulates intestinal wound healing 
following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 
2005;288:G621-629.  
Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks 
neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 
1990;99:202-206.  
Cai Y, Xin X, Shim GJ, et al., Pituitary adenylate cyclase activating polypeptide (PACAP) and 
vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third 
subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Endocrinology 
1997;138:2515-2520.  
Cao T, Gerard NP, Brain SD. Use of NK(1) knockout mice to analyze substance P-induced edema 
formation. Am J Physiol 1999;277:R476-R481.  
Cao T, Pinter E, Al-Rashed S, Gerard N, Hoult R, Brain SD. Neurokinin-1 receptor agonists are 
involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous 
microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol 
2000;164:5424-5429.  
Cardell LO, Uddman R, Luts A, Sundler F. Pituitary adenylate cyclase activating peptide (PACAP) in 
guinea-pig lung: distribution and dilatory effects. Regul Pept 1991;36:379-390.  
Cardell LO, Hjert O, Uddman R. The induction of nitric oxide-mediated relaxation of human isolated 
pulmonary arteries by PACAP. Br J Pharmacol 1997;120:1096-1100.  
 74 
Carlson RP, O'Neill-Davis L, Chang J, Lewis AJ. Modulation of mouse ear edema by cyclooxygenase 
and lipoxygenase inhibitors and other pharmacologic agents. Agents Actions 1985;17:197-
204.  
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: 
a heat-activated ion channel in the pain pathway. Nature 1997;389:816-824.  
Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a 
high threshold for noxious heat. Nature 1999;398:436-441.  
Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev 
Neurosci 2001;24:487-517.  
Cavani A, Hackett CJ, Wilson KJ, Rothbard JB, Katz SI. Characterization of epitopes recognized by 
hapten-specific CD4+ T cells. J Immunol 1995;154:1232-1238.  
Cesare P, Dekker LV, Sardini A, Parker PJ, McNaughton PA. Specific involvement of PKC-epsilon in 
sensitization of the neuronal response to painful heat. Neuron 1999;23:617-624.  
Chan CL, Facer P, Davis JB et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients 
with rectal hypersensitivity and faecal urgency. Lancet 2003; 361: 385-91.  
Chu CJ, Huang SM, De Petrocellis L, et al. N-oleoyldopamine, a novel endogenous capsaicin-like 
lipid that produces hyperalgesia. J Biol Chem 2003;278:13633-13639.  
Chuang HH, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin 
receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001;411:957-962.  
Clapham DE, Montell C, Schultz G, Julius D. International Union of Pharmacology. XLIII. 
Compendium of voltage-gated ion channels: transient receptor potential channels. Pharmacol 
Rev 2003; 55: 591-596.  
Coderre TJ, Basbaum AI, Levine DJ. Neural control of vascular permeability: interactions between 
primary afferents, mast cells, and sympathetic efferents. J Neurophysiol 1989;62:48-58.  
Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium 
experimental murine colitis. Lab Invest 1993;69:238-249.  
Dalsgaard T, Hannibal J, Fahrenkrug J, Larsen CR, Ottesen B. VIP and PACAP display different 
vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 2003;110:179-188.  
Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal 
hyperalgesia. Nature 2000;405:183-187.  
Dawson J, Sedgwick AD, Edwards JC, Lees P. A comparative study of the cellular, exudative and 
histological responses to carrageenan, dextran and zymosan in the mouse. Int J Tissue React 
1991;13:171-178.  
Dedov VN, Tran VH, Duke CC, et al. Gingerols: a novel class of vanilloid receptor (VR1) agonists. 
Br. J. Pharmacol. 2002;137:793-798.  
Delgado M, Garrido E, de la Fuente M, Gomariz RP. Pituitary adenylate cyclase-activating 
polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions. Peptides 
1996;17:1097-1105.  
Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary 
adenylate cyclase activating polypeptide prevent inducible nitric oxide synthase transcription 
 75 
in macrophages by inhibiting NF-kB and IFN regulatory factor 1 activation. J Immunol 
1999a;162:4685-4696.  
Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in 
LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J 
Neuroimmunol 1999b;96:167-181.  
Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary 
adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: 
in vitro and in vivo studies. J Immunol 1999c;162:1707-1716.  
Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate 
cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the 
inhibition of TNF-alpha and IL-6. J Immunol 1999d;162:1200-1205.  
Delgado M, Leceta J, Sun W, Gomariz RP, Ganea D. VIP and PACAP induce shift to a Th2 response 
by upregulating B7.2 expression. Ann N Y Acad Sci 2000;921:68-78.  
Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-
activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 
2002;16:1844-1846.  
Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in 
immunomodulation. Pharmacol Rev 2004;56:249-290.  
De Young LM, Kheifets JB, Ballaron SJ, Young JM. Edema and cell infiltration in the phorbol ester-
treated mouse ear are temporally separate and can be differentially modulated by 
pharmacologic agents. Agents Actions 1989;26:335-41.  
Dicicco-Bloom E, Lu N, Pintar JE, Zhang J. The PACAP ligand/receptor system regulates cerebral 
cortical neurogenesis. Ann N Y Acad Sci 1998;865:274-289.  
Dickinson T, Fleetwood-Walker SM, Mitchell R, Lutz EM. Evidence for roles of vasoactive intestinal 
polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors 
in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 
1997;31:175-185.  
Di Marzo V, Blumberg PM, Szállási Á. Endovanilloid signaling in pain. Curr Opin Neurobiol 
2002;12:372-379.  
Domek MJ, Iwata F, Blackman EI, et al. Anti-neutrophil serum attenuates dextran sulfate sodium-
induced colonic damage in the rat. Scand J Gastroenterol 1995;30:1089-1094.  
Dun EC, Huang RL, Dun SL, Sun NJ. Pituitary adenylate cyclase activating polypeptide-like 
immunoreactivity in human spinal cord and dorsal root ganglia. Brain Res 1996;721:233-
237.  
Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral 
arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or 
release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 1985;58:213-217.  
el Fahime E, Lutz-Bucher B, Felix JM, Koch B. Pituitary adenylate cyclase-activating polypeptide 
induces expression of corticosteroid-binding globulin in cultured fetal hepatocytes: synergy 
with tri-iodothyronine. Biochem J 1996;315:643-649.  
 76 
Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Ketotifen ameliorates capsaicin-augmented acetic 
acid-induced colitis. Dig Dis Sci 1995;40:503-509.  
Fahrenkrug J, Hannibal J. PACAP in visceral afferent nerves supplying the rat digestive and urinary 
tracts. Ann N Y Acad Sci 1998;865:542-546.  
Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor 
(VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J 
Cereb Blood Flow Metab 2000;20:1205-1214.  
Fang J, Payne L, Krueger JM. Pituitary adenylate cyclase activating polypeptide enhances rapid eye 
movement sleep in rats. Brain Res 1995;686:23-28.  
Felley CP, Qian JM, Mantey S, Pradhan T, Jensen RT. Chief cells possess a receptor with high 
affinity for PACAP and VIP that stimulates pepsinogen release. Am J Physiol 
1992;263:G901-907.  
Ferreira J, Triches KM, Medeiros R, Calixto JB. Mechanisms involved in the nociception produced by 
peripheral protein kinase c activation in mice. Pain 2005;117:171-181.  
Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent 
antagonized by a tripeptide analogue. Nature 1988;334:698-700.  
Follenfant RL, Nakamura-Craig M, Henderson B, Higgs GA. Inhibition by neuropeptides of 
interleukin-1 beta-induced, prostaglandin-independent hyperalgesia. Br J Pharmacol 
1989;98:41-43.  
Fujino K, Takami Y, de la Fuente SG, Ludwig KA, Mantyh CR. Inhibition of the vanilloid receptor 
subtype-1 attenuates TNBS-colitis. J Gastrointest Surg 2004;8:842-848.  
Fukuhara C, Suzuki N, Matsumoto Y, et al. Day-night variation of pituitary adenylate cyclase-
activating polypeptide (PACAP) level in the rat suprachiasmatic nucleus. Neurosci Lett 
1997;229:49-52.  
Gábor M, Rázga Z. Development and inhibition of mouse ear oedema induced with capsaicin. Agents 
Actions 1992;36:83-86.  
Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating 
polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral 
Biol Med 2002;13:229-237.  
Garcia-Martinez C, Humet M, Planells-Cases R, et al. Attenuation of thermal nociception and 
hyperalgesia by VR1 blockers. Proc Natl Acad Sci U S A 2002;99:2374-9.  
Garrido G, Gonzalez D, Lemus Y, et al. In vivo and in vitro anti-inflammatory activity of Mangifera 
indica L. extract (VIMANG). Pharmacol Res 2004;50:143-149.  
Gaytan F, Martinez-Fuentes AJ, Garcia-Navarro F, Vaudry H, Aguilar E. Pituitary adenylate cyclase-
activating peptide (PACAP) immunolocalization in lymphoid tissues of the rat. Cell Tissue 
Res 1994;276:223-227.  
Germonpré PR, Joos GF, Everaert E, Kips JC, Pauwels RA. Characterization of neurogenic 
inflammation in the airways of two highly inbred rat strains. Am J Respir Crit Care Med 
1995;152:1796-1804.  
 77 
Germonpré PR, Joos GF, Mekeirele K, Pauwels RA. Role of the 5-HT receptor in neurogenic 
inflammation in Fisher 344 rat airways. Eur J Pharmacol 1997;324:249-255.  
Gillardon F, Hata R, Hossmann KA. Delayed up-regulation of Zac1 and PACAP type I receptor after 
transient focal cerebral ischemia in mice. Brain Res Mol Brain Res 1998;61:207-210.  
Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. VIP-PACAP system in immunity: 
new insights for multitarget therapy. Ann NY Acad Sci 2006;1070:51-74.  
Goso C, Evangelista S, Tramontana M, Manzini S, Blumberg PM, Szallasi A. Topical capsaicin 
administration protects against trinitrobenzene sulfonic acid-induced colitis in the rat. Eur J 
Pharmacol 1993;249:185-190.  
Gottschall PE, Tatsuno I, Miyata A, Arimura A. Characterization and distribution of binding sites for 
the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 
1990;127:272-277.  
Grant A. Leukocytes and neurogenic inflammation. Inflammopharmacology 2002;9:403-420.  
Gray DW, Marshall I. Human alpha-calcitonin gene-related peptide stimulates adenylate cyclase and 
guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Br J Pharmacol 
1992;107:691-696.  
Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-
548.  
Grimaldi M, Cavallaro S. Functional and molecular diversity of PACAP/VIP receptors in cortical 
neurons and type I astrocytes. Eur J Neurosci 1999;11:2767-2772.  
Griswold DE, Martin LD, Badger AM, Breton J, Chabot-Fletcher M. Evaluation of the cutaneous anti-
inflammatory activity of azaspiranes. Inflamm Res 1998;47:56-61.  
Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 
2007;13:918-932.  
Grundy D. Neuroanatomy of visceral nociception: vagal and splanchnic afferent. Gut 2002;Suppl 1:i2-
5.  
Gunthorpe MJ, Benham CD, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor 
family of ion channels. Trends Pharmacol Sci 2002;23:183-191.  
Gutwald J, Goebeler M, Sorg C. Neuropeptides enhance irritant and allergic contact dermatitis. J 
Invest Dermatol 1991;96:695-698.  
Han SP, Naes L, Westfall TC. Calcitonin gene-related peptide is the endogenous mediator of 
nonadrenergic-noncholinergic vasodilation in rat mesentery. J Pharmacol Exp Ther 
1990;255:423-428.  
Hannibal J, Ekblad E, Mulder H, Sundler F, Fahrenkrug J. Pituitary adenylate cyclase activating 
polypeptide (PACAP) in the gastrointestinal tract of the rat: distribution and effects of 
capsaicin or denervation. Cell Tissue Res 1998;291:65-79.  
Hannibal J, Fahrenkrug J. Pituitary adenylate cyclase-activating polypeptide in intrinsic and extrinsic 
nerves of the rat pancreas. Cell Tissue Res 2000;299:59-70.  
Hartung HP, Toyka KV. Substance P, the immune system and inflammation. Int Rev Immunol 
1989;4:229-249.  
 78 
Hashimoto H, Nogi H, Mori K, et al. Distribution of the mRNA for a pituitary adenylate cyclase-
activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 
1996;371:567-577.  
Helyes Z, Németh J, Pintér E, Szolcsányi J. Inhibition by nociceptin of neurogenic inflammation and 
the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol 1997;121:613-
615.  
Helyes Z, Pintér E, Németh J, et al. Anti-inflammatory effect of synthetic somatostatin analogues in 
the rat. Br J Pharmacol 2001;134:1571-1579.  
Helyes Z, Pintér E, Németh J, Szolcsányi J. Pharmacological targets for the inhibition of neurogenic 
inflammation. Curr Med Chem AIAAA 2003;2:191-218.  
Helyes Z, Pinter E, Nemeth J, et al. Effects of the somatostatin receptor subtype 4 selective agonist J-
2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br J Pharmacol 
2006;149:405-415.  
Herbert MK, Hering S, Holzer P. Interleukin 1 beta, but not tumor necrosis factor, enhances 
neurogenic vasodilatation in the rat skin: involvement of nitric oxide. Can J Physiol 
Pharmacol 1995;73:1075-1079.  
Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express 
substance P and neurokinin-1 receptor. J Immunol 1997;159:5654-5660.  
Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. 
Pharmacol Rev 1991; 43: 143-201.  
Holzer P. Sensory neurone responses to mucosal noxae in the upper gut: relevance to mucosal 
integrity and gastrointestinal pain. Neurogastroenterol Motil 2002;14:459-475.  
Holzer P, Bartho L. Sensory neurons in the intestine. In: Geppetti P, Holzer P, eds. Neurogenic 
Inflammation. Boca Raton: CRC Press; 1996: 153-167.  
Holzer P, Maggi CA. Dissociation of dorsal root ganglion neurons into afferent and efferent-like 
neurons. Neuroscience 1998; 86: 389-398.  
Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. 
Pharmacol Ther 1997;73:173-217.  
Hökfelt T, Elde R, Johansson O, Luft R, Nilsson G, Arimura A. Immunohistochemical evidence for 
separate populations of somatostatin containing and substance P-containing primary afferent 
neurons in the rat. Neuroscience 1976;1:131-136.  
Huang MT, Liu Y, Ramji D, et al. Inhibitory effects of black tea theaflavin derivatives on 12-O-
tetradecanoylphorbol-13-acetate-induced inflammation and arachidonic acid metabolism in 
mouse ears. Mol Nutr Food Res 2006;50:115-122.  
Hughes SR, Brain SD. Nitric oxide-dependent release of vasodilator quantities of calcitonin gene-
related peptide from capsaicin-sensitive nerves in rabbit skin. Br J Pharmacol 1994;111:425-
430.  
Hunter DD, Myers AC, Undem BJ. Nerve growth factor-induced phenotypic switch in guinea pig 
airway sensory neurons. Am J Respir Crit Care Med 2000;161:1985-1990.  
 79 
Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of 
lioxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 
2000;97:6155-6160.  
Ichikawa H, Sugimoto T. Pituitary adenylate cyclase-activating polypeptide-immunoreactive nerve 
fibers in rat and human tooth pulps. Brain Res 2003;980:288-292.  
Inoue H, Asaka T, Nagata N, Koshihara Y. Mechanism of mustard oil-induced skin inflammation in 
mice. Eur J Pharmacol 1997;333:231-240.  
Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue 
distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811-819.  
Ishizuka Y, Kashimoto K, Mochizuki T, Sato K, Ohshima K, Yanaihara N. Cardiovascular and 
respiratory actions of pituitary adenylate cyclase-activating polypeptides. Regul Pept 
1992;40:29-39.  
Iwanaga T, Hoshi O, Han H, Fujita T. Morphological analysis of acute ulcerative colitis 
experimentally induced by dextran sulfate sodium in the guinea pig: some possible 
mechanisms of cecal ulceration. J Gastroenterol 1994;29:430-438.  
Jakab B, Reglodi D, Jozsa R, et al. Distribution of PACAP-38 in the central nervous system of various 
species determined by a novel radioimmunoassay. J Biochem Biophys Methods 2004;61:189-
198.  
Jancsó G, Király E, Jancsó-Gábor A. Pharmacologically induced selective degeneration of 
chemosensitive primary sensory neurons. Nature 1977;270:741-743.  
Jancsó N. Role of nerve terminals in the mechanism of inflammatory reactions. Bull Millard Fillmore 
Hosp, Buffalo, NY 1960;7:53-77.  
Jancsó N, Jancsó-Gábor A. Dauerausschaltung der chemischen Schmerzempfindlichkeit durch 
Capsaicin. Naunyn-Schmiedebergs Arch Exp Path Pharmak 1959;236:142-145.  
Jancsó N, Jancsó-Gábor A, Szolcsányi J. Direct evidence for neurogenic inflammation and its 
prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemoter 
1967;31:138-151.  
Jancsó N, Jancsó-Gábor A, Szolcsányi J. The role of sensory nerve endings in neurogenic 
inflammation induced in human skin and int he eye and paw of the rat. Br J Pharmacol 
Chemoter 1968;33:32-41.  
Jancsó-Gábor A, Szolcsányi J. Neurogenic inflammatory responses. J Dent Res 1972;51:264-269.  
Johnson MC, McCormack RJ, Delgado M, Martinez C, Ganea D. Murine T-lymphocytes express 
vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J Neuroimmunol 1996;68:109-119.  
Jordt SE, Bautista DM, Chuang HH, et al. Mustard oils and cannabinoids excite sensory nerve fibres 
through the TRP channel ANKTM1. Nature 2004;427:260-265.  
Kato H, Ito A, Kawanokuchi J, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) 
ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of 
antigen presenting cells. Mult Scler 2004;10:651-659.  
 80 
Kihara N, de la Fuente SG, Fujino K, Takahashi T, Pappas TN, Mantyh CR. Vanilloid receptor-1 
containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. 
Gut 2003;52:713-719.  
Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ. Vanilloid receptor 1 antagonists 
attenuate disease severity in dextran sulphate sodium-induced colitis in mice. 
Neurogastroenterol Motil 2004;16:811-818.  
Kinhult J, Uddman R, Laan M, Linden A, Cardell LO. Pituitary adenylate cyclase-activating peptide 
inhibits neutrophil chemotaxis. Peptides 2001;22:2151-2154.  
Kokkotou E, Torres D, Moss AC, et al. Corticotropin-releasing hormone receptor 2-deficient mice 
have reduced intestinal inflammatory responses. J Immunol 2006;177:3355-3361.  
Koltzenburg M, McMahon SB. Plasma extravasation int he rat urinary bladder following mechanical, 
electrical and chemical stimuli: evidence for a new population of chemosensitive primary 
sensory afferents. Neurosci Lett 1986;72:352-356.  
Konturek SJ, Jaworek J, Tasler J, Cieszkowski M,Pawlik W. Effect of substance P and its C-terminal 
hexapeptide on gastric and pancreatic secretion in the dog. Am J Physiol 1981;241:G74-G81.  
Koplas PA, Rosenberg RL, Oxford GS. The role of calcium in the desensitization of capsaicin 
responses in rat dorsal root ganglion neurons. J Neurosci 1997;17:3525-3537.  
Kozicz T, Vigh S, Arimura A. Axon terminals containing PACAP- and VIP-immunoreactivity form 
synapses with CRF-immunoreactive neurons in the dorsolateral division of the bed nucleus of 
the stria terminalis in the rat. Brain Res 1997;767:109-119.  
Krieglstein CF, Cerwinka WH, Laroux FS, et al. Regulation of murine intestinal inflammation by 
reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J 
Exp Med 2001;194:1207-1218.  
Kuchera S, Barth H, Jacobson P, Metz A, Schaechtele C, Schrier D. Anti-inflammatory properties of 
the protein kinase C inhibitor, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-
yl)-1H- pyrrole-2,5-dione monohydrochloride (GF109203X) in the PMA-mouse ear edema 
model. Agents Actions 1993;39 Spec No: C169-173.  
Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J 
Neuroimmunol 1998;86:80-86.  
Laird JM, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F. Deficits in visceral pain and 
hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience 
2000;98:345-352.  
Lam HC, Takahashi K, Ghatei MA, Kanse SM, Polak JM, Bloom SR. Binding sites of a novel 
neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung. Eur 
J Biochem 1990;193:725-729 . 
Lam FY, Ferrell WR. Inhibition of carrageenan-induced inflammation in the rat knee joint by 
substance P antagonist. Ann Rheum Dis 1989;48:928-935.  
Langley JN. Antidromic action. J Physiol 1923;57:428-446.  
 81 
Larsen JO, Hannibal J, Knudsen SM, Fahrenkrug J. Expression of pituitary adenylate cyclase-
activating polypeptide (PACAP) in the mesencephalic trigeminal nucleus of the rat after 
transsection of the masseteric nerve. Brain Res Mol Brain Res 1997;46:109-117.  
Lazar J, Braun DC, Toth A, et al. Kinetics of penetration influence the apparent potency of vanilloids 
on TRPV1. Mol Pharmacol 2006;69:1166-1173.  
Legradi G, Shioda S, Arimura A. Pituitary adenylate cyclase-activating polypeptide-like 
immunoreactivity in autonomic regulatory areas of the rat medulla oblongata. Neurosci Lett 
1994;176:193-196.  
Lembeck F, Starke K. Substance P and salivary secretion. Naunyn Schmiedebergs Arch Exp Pathol 
Pharmakol 1968;259:375-385.  
Le Meuth V, Farjaudon N, Bawab W, et al. Characterization of binding sites for VIP-related peptides 
and activation of adenylate cyclase in developing pancreas. Am J Physiol 1991;260:G265-74.  
Leung FW. Role of capsaicin-sensitive afferent nerves in mucosal injury and injury-induced 
hyperemia in rat colon. Am J Physiol 1992;262:G332-337.  
Levine JD, Moskowitz MA, Basbaum AI. The contribution of neurogenic inflammation in 
experimental arthritis. J Immunol 1985;135(2 Suppl):843s-847s.  
Linnik MD, Moskowitz MA. Identification of immunoreactive substance P in human and other 
mammalian endothelial cells. Peptides 1989;10:957-962.  
Liu L, Simon SA. Similarities and differences in the currents activated by capsaicin, piperine and 
zingerone in rat trigeminal ganglion cells. J Neurophysiol 1996;76:1858-1869.  
Liu L, Simon SA. The influence of removing extracellular Ca2+ in the desensitization responses to 
capsaicin, zingerone and olvanil in rat trigeminal ganglion neurons. Brain Res 1998;809:246-
252.  
Liu L, Welch JM, Erickson RP, Reinhart PH, Simon SA. Different responses to repeated applications 
of zingerone in behavioral studies, recordings from intact and cultured TG neurons, and from 
VR1 receptors. Physiol Behav 2000;69:177-186.  
Lomax AE, Furness JB. Neurochemical classification of enteric neurons in the guinea-pig distal 
colon. Cell Tissue Res 2000;302:59-72.  
Lundberg JM, Brodin E, Hua X, Saria A. Vascular permeability changes and smooth muscle 
contraction in relation to capsaicin-sensitive substance P afferents in the guinea pig. Acta 
Physiol Scand 1984;120:217-227.  
Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ. The VIP2 receptor: molecular 
characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS 
Lett 1993;334:3-8.  
Maggi CA. The pharmacology of the efferent function of sensory nerves. J Auton Pharmacol 
1991;11:173-208.  
Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from 
peripheral endings of sensory nerves. Prog Neurobiol 1995;45:1-98.  
Maggi CA. The effects of tachykinins on inflammatory and immune cells. Regul Pept 1997;70:75-90.  
 82 
Mantyh CR, Pappas TN, Lapp JA, et al. Substance P activation of enteric neurons in response to 
intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology 1996;111:1272-
1280.  
Massi M, Panocka I, de Caro G. The psychopharmacology of tachykinin NK-3 receptors in laboratory 
animals. Peptides 2000;21:1597-1609.  
Masuo Y, Noguchi J, Morita S, Matsumoto Y. Effects of intracerebroventricular administration of 
pituitary adenylate cyclase-activating polypeptide (PACAP) on the motor activity and 
reserpine-induced hypothermia in murines. Brain Res 1995;700:219-226.  
Masuo Y, Matsumoto Y, Morita S, Noguchi J. A novel method for counting spontaneous motor 
activity in the rat. Brain Res Brain Res Protoc 1997;1:321-326.  
McCafferty DM, Wallace JL, Sharkey KA. Effects of chemical sympathectomy and sensory nerve 
ablation on experimental colitis in the rat. Am J Physiol 1997;272:G272-280.  
McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the 
calcitonin-receptor-like receptor. Nature 1998;393:333-339.  
Mirabella N, Squillacioti C, Germano G, Varricchio E, Paino G. Pituitary adenylate cyclase activating 
peptide (PACAP) immunoreactivity in the ureter of the duck. Cell Tissue Res 2001;305:341-
349.  
Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which 
stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989;164:567-
574.  
Mizuno Y, Kondo K, Terashima Y, Arima H, Murase T, Oiso Y. Anorectic effect of pituitary 
adenylate cyclase activating polypeptide (PACAP) in rats: lack of evidence for involvement 
of hypothalamic neuropeptide gene expression. J Neuroendocrinol 1998;10:611-616.  
Moller K, Zhang YZ, Hakanson R, et al. Pituitary adenylate cyclase activating peptide is a sensory 
neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 
1993;57:725-732.  
Moller M, Fahrenkrug J, Hannibal J Innervation of the rat pineal gland by pituitary adenylate cyclase-
activating polypeptide (PACAP)-immunoreactive nerve fibres. Cell Tissue Res 
1999;296:247-257.  
Morley JE, Horowitz M, Morley PM, Flood JF. Pituitary adenylate cyclase activating polypeptide 
(PACAP) reduces food intake in mice. Peptides 1992;13:1133-1135.  
Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model 
of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.  
Mourad FH, Barada KA, Bou Rached NA, Khoury CI, Saade NE, Nassar CF. Inhibitory effect of 
experimental colitis on fluid absorption in rat jejunum: role of the enteric nervous system, 
VIP, and nitric oxide. Am J Physiol Gastrointest Liver Physiol 2006;290:G262-268.  
Mulder H, Uddman R, Moller K, et al. Pituitary adenylate cyclase activating polypeptide expression 
in sensory neurons. Neuroscience 1994;63:307-312.  
Mulder H, Uddman R, Moller K, et al. Pituitary adenylate cyclase activating polypeptide is expressed 
in autonomic neurons. Regul Pept 1995;59:121-128.  
 83 
Mungan Z, Hammer RA, Akarca US, Komaki G, Ertan A, Arimura A. Effect of PACAP on gastric 
acid secretion in rats. Peptides 1995;16:1051-1056.  
Narita M, Dun SL, Dun NJ, Tseng LF. Hyperalgesia induced by pituitary adenylate cyclase-activating 
polypeptide in the mouse spinal cord. Eur J Pharmacol 1996;311:121-126.  
Naukkarinen A, Jarvikallio A, Lakkakorpi J, Harvima IT, Harvima RJ, Horsmanheimo M. 
Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J 
Pathol 1996;180:200-205.  
Nelson MT, Huang Y, Brayden JE, Hescheler J, Standen NB. Arterial dilations in response to 
calcitonin gene-related peptide involve activation of K+ channels. Nature 1990;344:770-773.  
Németh J, Helyes Z, Görcs T, Gárdi J, Pintér E, Szolcsányi J. Development of somatostatin 
radioimmunoassay for the measurement of plasma and tissue contents of hormone. Acta 
Physiol Hung 1996;84:313-315.  
Németh J, Görcs T, Helyes Z, et al. Development of a new sensitive CGRP radioimmunoassay for 
neuropharmacological research. Neurobiology (Bp) 1998;6:473-475.  
Németh J, Oroszi G, Thán M, et al. Substance P radioimmunoassay for quantitative characterization of 
sensory neurotransmitter release. Neurobiology (Bp) 1999;7:437-444.  
Neumann S, Doubell TP, Leslie T, Woolf CJ. Inflammatory pain hypersensitivity mediated by 
phenotypic switch in myelinated primary sensory neurons. Nature 1996;384:360-364. 
Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate 
established experimental colitis in mice. J Exp Med 1995;182:1281-1290.  
Njuki F, Nicholl CG, Howard A, et al. A new calcitonin-receptor-like sequence in rat pulmonary 
blood vessels. Clin Sci (Lond) 1993;85:385-388.  
Nomura M, Ueta Y, Serino R, Kabashima N, Shibuya I, Yamashita H. PACAP type I receptor gene 
expression in the paraventricular and supraoptic nuclei of rats. Neuroreport 1996;8:67-70.  
Okayama M, Tsubouchi R, Kato S, Takeuchi K. Protective effect of lafutidine, a novel histamine H2-
receptor antagonist, on dextran sulfate sodium-induced colonic inflammation through 
capsaicin-sensitive afferent neurons in rats. Dig Dis Sci 2004;49:1696-704.  
Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the 
induction of reliable experimental acute and chronic ulcerative colitis in mice. 
Gastroenterology 1990;98:694-702.  
Onaga T, Uchida M, Kimura M, et al. Effect of pituitary adenylate cyclase-activating polypeptide on 
exocrine and endocrine secretion in the ovine pancreas. Comp Biochem Physiol C Pharmacol 
Toxicol Endocrinol 1996;115:185-193.  
Otto C, Zuschratter W, Gass P, Schutz G. Presynaptic localization of the PACAP-typeI-receptor in 
hippocampal and cerebellar mossy fibres. Brain Res Mol Brain Res 1999;66:163-174.  
Page NM, Bell NJ, Gardiner SM, et al. Characterization of the endokinins: human tachykinins with 
cardiovascular activity. Proc Natl Acad Sci U S A 2003;100:6245-6250.  
Pascual DW, Bost KL. Substance P production by P388D1 macrophages: a possible autocrine 
function for this neuropeptide. Immunology 1990;71:52-56.  
 84 
Patacchini R, Maggi CA. Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 
2001;429:13-21.  
Patacchini R, Maggi A, Meli A. Capsaicin-like activity of some natural pungent substances on 
peripheral endings of visceral afferents. Naunyn Schmiedeberg’s Arch Pharmacol 
1990;342:72-77.  
Patterson LM, Zheng H, Ward SM, Berthoud HR. Vanilloid receptor (VR1) expression in vagal 
afferent neurons innervating the gastrointestinal tract. Cell Tissue Res 2003;311:277-287.  
Philippe D, Chakass D, Thuru X, et al. Mu opioid receptor expression is increased in inflammatory 
bowel diseases: implications for homeostatic intestinal inflammation. Gut 2006;55:815-823.  
Pisegna JR, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-
activating polypeptide type I receptor. Proc Natl Acad Sci U S A 1993;90:6345-6349.  
Poonyachoti S, Kulkarni-Narla A, Brown DR. Chemical coding of neurons expressing delta- and 
kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. 
Cell Tissue Res 2002;307:23-33.  
Pozo D, Delgado M, Martinez C, Gomariz RP, Guerrero JM, Calvo JR. Functional characterization 
and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I 
receptors in rat peritoneal macrophages. Biochim Biophys Acta 1997;1359:250-262.  
Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological 
roles. Neuropeptides 1998;32:1-49.  
Quayle JM, Bonev AD, Brayden JE, Nelson MT. Calcitonin gene-related peptide activated ATP-
sensitive K+ currents in rabbit arterial smooth muscle via protein kinase A. J Physiol 
1994;475:9-13.  
Qian BF, Hammarstrom ML, Danielsson A. Differential expression of vasoactive intestinal 
polypeptide receptor 1 and 2 mRNA in murine intestinal T lymphocyte subtypes. J 
Neuroendocrinol 2001;13:818-825.  
Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-
inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 
2004;126:520-528.  
Racz B, Gasz B, Borsiczky B, et al. Protective effects of pituitary adenylate cyclase activating 
polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp 
Endocrinol 2007;153:115-123.  
Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate 
experimental colitis in rats and mice. Infect Immun 2001;69:2277-2285.  
Raufman JP, Malhotra R, Singh L. PACAP-38, a novel peptide from ovine hypothalamus, is a potent 
modulator of amylase release from dispersed acini from rat pancreas. Regul Pept 
1991;36:121-129.  
Raychaudhuri A, Colombo C, Pastor G, Wong M, Jeng AY. Effect of capsaicin on carrageenan-
induced inflammation in rat pleurisy and exudate substance P levels. Agent Actions 
1991;34:251-259.  
 85 
Reimer M, Moller K, Sundler F, Hannibal J, Fahrenkrug J, Kanje M. Increased expression, axonal 
transport and release of pituitary adenylate cyclase-activating polypeptide in the cultured rat 
vagus nerve. Neuroscience 1999;88:213-222.  
Reinshagen M, Patel A, Sottili M, et al. Protective function of extrinsic sensory neurons in acute 
rabbit experimental colitis. Gastroenterology 1994;106:1208-1214.  
Reinshagen M, Patel A, Sottili M, French S, Sternini C, Eysselein VE. Action of sensory neurons in 
an experimental at colitis model of injury and repair. Am J Physiol 1996;270:G79-86.  
Reinshagen M, Egger B, Procaccino F, et al. Neuropeptides in inflammatory bowel disease: an update. 
Inflamm Bowel Dis 1997;3:303-313.  
Reinshagen M, Flamig G, Ernst S, et al. Calcitonin gene-related peptide mediates the protective effect 
of sensory nerves in a model of colonic injury. J Pharmacol Exp Ther 1998;286:657-661.  
Rene F, Monnier D, Gaiddon C, Felix JM, Loeffler JP. Pituitary adenylate cyclase-activating 
polypeptide transduces through cAMP/PKA and PKC pathways and stimulates 
proopiomelanocortin gene transcription in mouse melanotropes. Neuroendocrinology 
1996;64:2-13.  
Renzi D, Pellegrini B, Tonelli F, Surrenti C, Calabro A. Substance P (neurokinin-1) and neurokinin A 
(neurokinin-2) receptor gene and protein expression in the healthy and inflamed human 
intestine. Am J Pathol 2000;157:1511-1522.  
Romero A, Planas E, Poveda R, Sanchez S, Pol O, Puig MM. Anti-exudative effects of opioid 
receptor agonists in a rat model of carrageenan-induced inflammation of the paw. Eur J 
Pharmacol 2005;511:207-217.  
Saotome M, Uchida Y, Nomura A, Endo T, Hasegawa S. Pituitary adenylate cyclase activating 
peptide induces cGMP-mediated relaxation in guinea-pig airways. Pulm Pharmacol Ther 
1998;11:281-285.  
Schoenfeld LK, Souder JA, Hardwick JC. Pituitary adenylate cyclase-activating polypeptide 
innervation of the mudpuppy cardiac ganglion. Brain Res 2000;882:180-190.  
Setoyama H, Imaoka A, Ishikawa H, Umesaki Y. Prevention of gut inflammation by Bifidobacterium 
in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from 
ulcerative colitis patients. Microbes Infect 2003;5:115-122.  
Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase 
activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000;21:619-670.  
Sheward WJ, Lutz EM, Harmar AJ. The distribution of vasoactive intestinal peptide2 receptor 
messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. 
Neuroscience 1995;67:409-418.  
Shigyo M, Aizawa H, Inoue H, Matsumoto K, Takata S, Hara N. Pituitary adenylate cyclase 
activating peptide regulates neurally mediated airway responses. Eur Respir J 1998;12:64-70.  
Shioda S, Shuto Y, Somogyvari-Vigh A, et al. Localization and gene expression of the receptor for 
pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res 1997;28:345-
354.  
 86 
Silvan AM, Abad MJ, Bermejo P, Villar A. Inhibition by hydroxyachillin, sesquiterpene lactone from 
Tanacetum microphyllum, of PMA-induced mouse ear oedema. Inflamm Res 1996;45:289-
292.  
Simonneaux V, Kienlen-Campard P, Loeffler JP, et al. Pharmacological, molecular and functional 
characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating 
polypeptide receptors in the rat pineal gland. Neuroscience 1998;85:887-896.  
Skakkebaek M, Hannibal J, Fahrenkrug J. Pituitary adenylate cyclase activating polypeptide (PACAP) 
in the rat mammary gland. Cell Tissue Res 1999;298:153-159.  
Smith GD, Gunthorpe MJ, Kelsell RE, et al. TRPV3 is a temperature-sensitive vanilloid receptor-like 
protein. Nature 2002;418:186-190.  
Somogyvari-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential 
neuroprotective peptide. Curr Pharm Des 2004;10:2861-2889.  
Spengler D, Villalba M, Hoffmann A, et al. Regulation of apoptosis and cell cycle arrest by Zac1, a 
novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J 
1997;16:2814-2825.  
Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE. Identification 
of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in 
human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept 
1999;80:49-55.  
Stevceva L, Pavli P, Husband A, Ramsay A, Doe WF. Dextran sulphate sodium-induced colitis is 
ameliorated in interleukin 4 deficient mice. Genes Immun 2001;2:309-316.  
Strange-Vognsen HH, Arnbjerg J, Hannibal J. Immunocytochemical demonstration of pituitary 
adenylate cyclase activating polypeptide (PACAP) in the porcine epiphyseal cartilage canals. 
Neuropeptides 1997;31:137-141.  
Suda K, Smith DM, Ghatei MA, Bloom SR.  Investigation of the interaction of VIP binding sites with 
VIP and PACAP in human brain. Neurosci Lett 1992;137:19-23.  
Szállási Á, Blumberg PM. Neurogenic component of phorbol ester-induced mouse skin inflammation. 
Cancer Res 1989;49:6052-6057.  
Szállási Á, Blumberg PM. Resiniferatoxin and its analogs provide novel insights into the 
pharmacology of the vanilloid (capsaicin) receptor. Life Sci 1990;47:1399-408.  
Szállási Á, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 
1999;51:159-212.  
Szolcsányi J. A pharmacological approach to elucidation of the role of different nerve fibres and 
receptor endings in mediation of pain. J Physiol (Paris) 1977;73:251-259.  
Szolcsányi J. Capsaicin type pungent agents producing pyrexia. In: Milton AS, ed. Handbook of 
experimental pharmacology. Berlin: Springer; 1982: 437-478.  
Szolcsányi J. Tetrodotoxin-resistant non-cholinergic neurogenic contraction evoked by capsaicinoids 
and piperine on guinea-pig trachea. Neurosci Lett 1983;42:83-88.  
 87 
Szolcsányi J. Capsaicin-sensitive chemoceptive neural system with dual sensory-efferent function. In: 
Chahl LA, Szolcsányi J, Lembeck F, eds. Antidromic Vasodilatation and Neurogenic 
Inflammation. Budapest: Akadémiai Kiadó, 1984:27-55.  
Szolcsányi J. Capsaicin-sensitive sensory nerve terminals width local and systemic efferent functions: 
facts and scopes of an unorthodox neuroregulatory mechanism. Prog Brain Res 
1996;113:343-359.  
Szolcsányi J. Capsaicin receptors as target molecules on nociceptors for development of novel 
analgetic agents. In: Kéri Gy, Tóth J, eds. Molecular Pathomechanisms and New Trends in 
Drug Research. New York: Taylor and Francis Publ., 2002:319-333.  
Szolcsányi J, Jancsó-Gábor A. Sensory effects of capsaicin congeners I. Relationship between 
chemical structure and pain-producing potency of pungent agents. Arzneimittelforschung 
1975;25:1877-1881.  
Szolcsányi J, Pethő G. History of ion channels in the pain sensory system. In: Oh U, ed. The 
Nociceptive Membrane. San Diego: Academic Press, 2006:21-72.  
Szolcsányi J, Szállási Á, Szállási Z, Joo F, Blumberg PM. Resiniferatoxin: an ultrapotent selective 
modulator of capsaicin-sensitive primary afferent neurons. J Pharmacol Exp Ther 
1990;255:923-928.  
Szolcsányi J, Pintér E, Helyes Zs, Oroszi G, Németh J. Systemic anti-inflammatory effect induced by 
counter-irritation through a local release of somatostatin from nociceptors. Br J Pharmacol 
1998a;125:916-922.  
Szolcsányi J, Helyes Zs, Oroszi G, Németh J, Pintér E. Release of somatostatin and its role in the 
mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres 
of rat sciatic nerve. Br J Pharmacol 1998b;123:936-942.  
Talero E, Sanchez-Fidalgo S, Calvo JR, Motilva V. Chronic administration of galanin attenuates the 
TNBS-induced colitis in rats. Regul Pept 2007;141:96-104.  
Tamaru T, Kobayashi H, Kishimoto S, Kajiyama G, Shimamoto F, Brown WR. Histochemical study 
of colonic cancer in experimental colitis of rats. Dig Dis Sci 1993;38:529-537.  
Tatsuno I, Gottschall PE, Arimura A. Specific binding sites for pituitary adenylate cyclase activating 
polypeptide (PACAP) in rat cultured astrocytes: molecular identification and interaction with 
vasoactive intestinal peptide (VIP). Peptides 1991;12:617-621.  
Tessner TG, Cohn SM, Schloemann S, Stenson WF. Prostaglandins prevent decreased epithelial cell 
proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 
1998;115:874-882.  
Tippins JR, Morris HR, Panico M, et al. The myotropic and plasma-calcium modulating effects of 
calcitonin gene-related peptide (CGRP). Neuropeptides 1984;4:425-434.  
Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple 
pain-producing stimuli. Neuron 1998;21:531-543.  
Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP 
receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad 
Sci U S A 2001;98:6951-6.  
 88 
Tornoe K, Hannibal J, Georg B, et al. PACAP 1-38 as neurotransmitter in the porcine antrum. Regul 
Pept 2001;101:109-121.  
Trevisani M, Smart D, Gunthorpe MJ, et al. Ethanol elicits and potentiates nociceptor responses via 
the vanilloid receptor-1. Nat Neurosci 2002;5:546-551.  
Tsuchida K, Shigemoto R, Yokota Y, Nakanishi S. Tissue distribution and quantitation of the mRNAs 
for three rat tachykinin receptors. Eur J Biochem 1990;193:751-757.  
Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar 
specificity and complementary distributions. Endocrinology 1994;135:2662-2680.  
Varga A, Bölcskei K, Szőke É, et al. Relative roles of protein kinase A and protein kinase C in 
modulation of transient receptor potential vanilloid type 1 receptor responsiveness in rat 
sensory neurons in vitro and peripheral nociceptors in vivo. Neuroscience 2006;140:645-657.  
Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-
activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 
2000;52:269-324.  
Verdu EF, Bercik P, Cukrowska B, et al. Oral administration of antigens from intestinal flora 
anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin 
Exp Immunol 2000;120:46-50.  
Vetuschi A, Latella G, Sferra R, Caprilli R, Gaudio E. Increased proliferation and apoptosis of colonic 
epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 2002;47:1447-
1457.  
Wang ZY, Alm P, Hakanson R. Distribution and effects of pituitary adenylate cyclase-activating 
peptide in the rabbit eye. Neuroscience 1995;69:297-308.  
Wang ZY, Waldeck K, Grundemar L, Hakanson R. Ocular inflammation induced by 
electroconvulsive treatment: contribution of nitric oxide and neuropeptides mobilized from 
C-fibres. Br J Pharmacol 1997;120:1491-1496.  
Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor 
(VR1) in the gastrointestinal tract. J Comp Neurol 2003; 465: 121-135.  
Warren JB, Donnelly LE, Cullen S, et al. Pituitary adenylate cyclase activating polypeptide: a novel, 
long-lasting, endothelium-independent vasorelaxant. Eur J Pharmacol 1991;197:131-134.  
Warren JB, Wilson AJ, Loi RK, Coughlan ML. Opposing roles of cyclic AMP in the vascular control 
of edema formation. FASEB J 1993;7:1394-1400.  
Watanabe H, Vriens J, Suh SH, Benham CD, Droogmans G, Nilius B. Heat-evoked activation of 
TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial 
cells. J. Biol. Chem. 2002;277:47044-47051.  
Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 
1996;157:355-357.  
Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res 
Tech 2001;53:167-178.  
 89 
Winding B, Wiltink A, Foged NT. Pituitary adenylyl cyclase-activating polypeptides and vasoactive 
intestinal peptide inhibit bone resorption by isolated rabbit osteoclasts. Exp Physiol 
1997;82:871-886.  
Wong AO, Leung MY, Shea WL, Tse LY, Chang JP, Chow BK. Hypophysiotropic action of pituitary 
adenylate cyclase-activating polypeptide (PACAP) in the goldfish: immunohistochemical 
demonstration of PACAP in the pituitary, PACAP stimulation of growth hormone release 
from pituitary cells, and molecular cloning of pituitary type I PACAP receptor. 
Endocrinology 1998;139:3465-379.  
Yamada M, Ohkusa T, Okayasu I. Occurrence of dysplasia and adenocarcinoma after experimental 
chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 1992;33:1521-
1527.  
Yon L, Breault L, Contesse V, et al. Localization, characterization, and second messenger coupling of 
pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland 
during the second trimester of gestation. J Clin Endocrinol Metab 1998;83:1299-1305.  
Young JM, Wagner BM, Spires DA. Tachyphylaxis in 12-0-tetradecanoylphorbol acetate- and 
arachidonic acid-induced ear edema. J Invest Dermatol 1983;80:48-52.  
Zhang Q, Shi TJ, Ji RR, et al. Expression of pituitary adenylate cyclase-activating polypeptide in 
dorsal root ganglia following axotomy: time course and coexistence. Brain Res 
1995;705:149-158.  
Zhang Y, Malmberg AB, Sjolund B, Yaksh TL. The effect of pituitary adenylate cyclase activating 
peptide (PACAP) on the nociceptive formalin test. Neurosci Lett 1996;207:187-190.  
Zhang Y, Malmberg AB, Yaksh TL, Sjolund B, Sundler F, Hakanson R. Capsaicin-evoked release of 
pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide 
(CGRP) from rat spinal cord in vivo. Regul Pept 1997;69:83-87.  
Zhang YZ, Hannibal J, Zhao Q, et al. Pituitary adenylate cyclase activating peptide expression in the 
rat dorsal root ganglia: up-regulation after peripheral nerve injury. Neuroscience 
1996;74:1099-1110.  
Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S. PACAP and its receptors exert 
pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr 
Protein Pept Sci 2002;3:423-439.  
Zhou L, Zhang Q, Stein C, Schafer M. Contribution of opioid receptors on primary afferent versus 
sympathetic neurons to peripheral opioid analgesia. J Pharmacol Exp Ther 1998;186:1000-
1006.  
 
 90 
List of publications  
 
 
Papers related to the thesis  
 
Németh J, Reglődi D, Pozsgai G, et al. Effect of pituitary adenylate cyclase 
activating polypeptide-38 on sensory neuropeptide release and neurogenic 
inflammation in rats and mice. Neuroscience 2006;143:223-230. IF: 3.410 
Helyes Zs, Pozsgai G, Börzsei R, et al. Inhibitory effect of PACAP-38 on acute 
neurogenic and non-neurogenic inflammatory processes in the rat. Peptides 
2007;28:1847-1855. IF: 2.231 
Pozsgai G, Sándor K, Perkecz A, et al. Topical acetone treatment induces neurogenic 
oedema on the sensitized mouse ear: an in vivo study using transient receptor 
potencial vanilloid 1 (TRPV1) receptor knockout mice. Inflamm Res 2007 (in 
press). IF: 1.210 
Pozsgai G, Perkecz A, Markovics D, Szolcsányi J, Pintér E. Investigation of the role 
of transient receptor potential vanilloid 1 receptor in dextran sulphate sodium 
induced colitis using gene deficient mice. Neurogastroenterol Motil 2007 
(prepared for submission).  
 
Impact factors of manuscripts: 6.851 
 
 
Abstracts related to the thesis 
 
Pozsgai G, Sándor K, Perkecz A, Szolcsányi J, Pintér E. Phorbol 12-myristate 13-
acetate (PMA) induced ear inflammation in transient receptor potencial 
vanilloid 1 (TRPV1) receptor transgenic mice. Acta Pharmacol Sin 
2006;Suppl. 1:111. IF: 1.123 
 
 91 
Other publications 
 
 
Manuscripts 
 
Bánvölgyi Á., Pozsgai G, Brain SD, et al. Mustard oil induces a TRPV1 receptor 
independent neurogenic inflammation and a non-neurogenic cellular 
inflammatory component. Neuroscience 2004;125:449-459. IF: 3.456 
Bánvölgyi Á, Pálinkás L, Berki T, et al. Evidence for a novel protective role of the 
vanilloid TRPV1 receptor in a cutaneous contact allergic dermetitis model. J 
Neuroimmunol 2005;169:86-96. IF: 2.824 
Helyes Zs, Pintér E, Németh J, et al. Effects of the somatostatin receptor subtype 4 
selective agonist J-2156 on sensory neuropeptide release and inflammatory 
reactions in rodents. Br J Pharmacol 2006;149:405-415. IF: 3.410 
Helyes Zs, Elekes K, Németh J, et al. Role of Transient Receptor Potential Vanilloid 
1 receptors in endotoxin-induced airway inflammation in the mouse. Am J 
Physiol Lung Cell Mol Physiol 2007;292:L1173-1181. IF: 3.939 
Elekes K., Helyes Zs, Németh J, et al. Role of capsaicin-sensitive afferents and 
sensory neuropeptides in endotoxin-induced airway inflammation and 
consequent bronchial hyperreactivity in the mouse. Regul Pept 2007;141:44-
54. IF: 2.272 
Elekes K, Helyes Z, Kereskai L, et al. Inhibitory effects of synthetic somatostatin 
receptor subtype 4 agonists on acute and chronic airway inflammation and 
hyperreactivity in the mouse. Eur J Pharmacol 2007 (in press). IF: 2.522 
 
Total impact factors of manuscripts: 25.274 
Independent citations: 15 
Total citations: 17 
 
 
Abstracts 
 
 92 
Bánvölgyi Á, Pozsgai G, Szolcsányi J, Davis JB, Brain SD, Pintér E. 
Characterization of mustard oil-induced ear oedema in BALB/c, NK1 and 
VR1 receptor knockout mice. Neuropeptides 2003;37:190. IF: 2.153 
Pozsgai G, Helyes Zs, Szabó Á, et al. Pharmacological investigation of a selective 
non-peptide somatostatin receptor type 4 agonist in vitro and in vivo. 
Neuropeptides 2005;39:619. IF: 2.155 
Pintér E, Bánvölgyi Á, Pálinkás L, et al. Evidence for a novel protective role of the 
vanilloid receptor in cutaneous inflammatory models. Neuropeptides 
2005;39:606. IF: 2.155 
Sándor K, Szabó Á, Németh J, et al. Regulatory role of TRPV1 receptors in chronic 
neropathic hyperalgesia models in mice. Neuropeptides 2005;39:619. IF: 
2.155 
Elekes K, Németh J, Sándor K, et al. Role of the TRPV1 receptor in subacute airway 
inflammatory model of the mouse. Neuropeptides 2005;39:625. IF: 2.155 
Horváth P, Németh J, Helyes Zs, et al. The effect of neuropeptides in cisplatin 
induced sensorial neuropathy. Neuropeptides 2005;39:616. IF: 2.155 
Helyes Zs, Elekes K, Németh J, et al. TRPV1 receptor-mediated release of the 
inhibitory neuropeptide somatostatin in murine airway inflammatory model. 
Neuropeptides 2006;40:155. IF: 2.155 
Pintér E, Helyes Zs, Pozsgai G, et al. Characterization of anti-inflmmatory actions of 
a novel selective non-peptide somatostatin 4 receptor agonist in rodents. 
Neuropeptides 2006;40:156. IF: 2.155 
Pintér E, Helyes Zs, Németh J, et al. Anti-inflammatory effect of somatostatin 
receptor subtype 4 selective agonist J-2156 in rodents. Acta Pharmacol Sin 
2006;27(suppl 1):277. IF: 1.123 
Elekes K, Helyes Zs, Németh J, et al. Inhibitory effect of somatostatin released by 
TRPV1 receptor activation on endotoxin-induced airway inflammation and 
hyperreactivity in mice. Acta Pharmacol Sin 2006;27(suppl 1): 381. IF: 1.123 
Helyes Zs, Elekes K, Sándor K, et al. Role of capsaicin-sensitive afferents in 
endotoxin-induced inflammation and hyperresponsiveness of the mouse 
airways. Acta Pharmacol Sin 2006;27(suppl 1):106. IF: 1.123 
Helyes Zs,
 
Elekes K, Németh J, et al. Role of capsaicin-sensitive sensory nerves and 
the TRPV1 capsaicin receptor in endotoxin-induced airway inflammation and 
hyperreactivity in mice. J Neuroimmunol 2006;178(suppl 2):108. IF: 2.824 
 93 
 
 
 94 
Oral presentations and posters 
 
 
International conferences 
 
Bánvölgyi Á, Pozsgai G, Helyes Zs, Szolcsányi J, Brain SD, Pintér E. Role of 
neurokinin 1 (NK1) and vanilloid 1 (VR1) receptors in oxazolone-induced 
delayed-type hypersensitivity reaction (DTH) in mice. 4th International 
Conference of PhD Students, Miskolc, Hungary, 2003.  
Pintér E, Sándor K, Helyes Zs, Pozsgai G, Szolcsányi J. Somatostatin 4 (sst4) 
receptor mediates inhibitory effects on carrageenan-induced paw 
inflammation in rodents. European Neuropeptide Club, 17
th
 Annual Meeting, 
Santorini, Greece, 2007.  
Pozsgai G, Sándor K, Perkecz A, et al. TRPV1 receptor independent potentiating 
action of phorbol 12-myristate 13-acetate evoked ear inflammation on 
acetone-induced contralateral ear oedema in mice. European Neuropeptide 
Club, 17
th
 Annual Meeting, Santorini, Greece, 2007.  
Helyes Zs, Elekes K, Pozsgai G, et al. Role of the somatostatin receptor subtype 4 
(sst4) in endotoxin-induced airway inflammation: in vivo studies on gene-
deficient mice. European Neuropeptide Club, 17
th
 Annual Meeting, Santorini, 
Greece, 2007.  
Börzsei R, Pozsgai G, Bagoly T, et al. Inhibitory action of endomorphin-1, a novel 
endogenous opioid peptide, on sensory neuropeptide release and neurogenic 
inflammation in rats and mice. European Neuropeptide Club, 17
th
 Annual 
Meeting, Santorini, Greece, 2007.  
 
 
Hungarian conferences 
 
Bánvölgyi Á, Pozsgai G, Dénes V, Szolcsányi J, Brain SD, Pintér E. A mustárolaj 
okozta gyulladás jellemzése BALB/c, NK1- és VR1 receptor hiányos 
 95 
transzgenikus egereken. Magyar Kísérletes és Klinikai Farmakológiai 
Társaság V. Konferenciája, Debrecen, 2002.  
Bánvölgyi Á, Pozsgai G, Pálinkás L, et al. A szenzoros neuropeptidek hatásának 
vizsgálata az oxazolonnal kiváltott késői típusú hiperszenzitív reakcióban 
egéren. Magyar Klinikai Farmakológusok V. Kongresszusa és MFT 
Immunfarmakológiai Szekció Ülése, Debrecen, 2003.  
Bánvölgyi Á, Pozsgai G, Szabó Á, et al. A mustárolajjal kiváltott fülgyulladás 
jellemzése BALB/c, NK1 és VR1 receptor génhiányos egerekben. Magyar 
Élettani Társaság (MÉT) LXVII. Vándorgyűlése, Pécs, 2003.  
Helyes Zs, Németh J, Elekes K, et al. A szelektív szomatosztatin 4 (sstr4) agonista 
KD5621 farmakológiai vizsgálata in vitro és in vivo. Magyar Idegtudományi 
Társaság Konferenciája, Pécs, 2005.  
Elekes K, Helyes Zs, Németh J, et al. A TRPV1 receptor szerepének vizsgálata egér 
szubakut légúti gyulladás modellben. Magyar Idegtudományi Társaság 
Konferenciája, Pécs, 2005.  
Elekes K, Németh J, Sándor K, et al. TRPV1 receptor-mediated release of the 
inhibitory neuropeptide somatostatin in murine airway inflammatory model. 
Magyar Kísérletes és Klinikai Farmakológiai Társaság, a Magyar 
Experimentális Farmakológia Tavaszi Szimpóziuma, Budapest, 2005.  
Pozsgai G, Helyes Zs, Szabó Á, et al. Investigation of a selective non-peptide 
somatostatin receptor type 4 agonist in different inflammatory models. 
Magyar Kísérletes és Klinikai Farmakológiai Társaság, a Magyar 
Experimentális Farmakológia Tavaszi Szimpóziuma, Budapest, 2005.  
Sándor K, Helyes Zs, Varga A, et al. Examination of novel TRPV1 receptor 
antagonists in vitro and in vivo in the rat. Magyar Kísérletes és Klinikai 
Farmakológiai Társaság, a Magyar Experimentális Farmakológia Tavaszi 
Szimpóziuma, Budapest, 2005.  
Szabó Á, Helyes Zs, Pintér E, et al. Role of the TRPV1 receptor in chronic arthritis 
and bleomycin-induced scleroderma model in the mouse. Magyar Kísérletes 
és Klinikai Farmakológiai Társaság, a Magyar Experimentális Farmakológia 
Tavaszi Szimpóziuma, Budapest, 2005.  
 96 
Sándor K, Helyes Zs, Varga A, et al. Az SB366791 kódjelű TRPV1 receptor 
antagonista hatástani vizsgálata patkányban. Magyar Fájdalom Társaság 
Kongresszusa, Siófok, 2005.  
Elekes K, Helyes Zs, Sándor K, et al. A szelektív szomatosztatin 4 receptor (sst4) 
agonista J-2156 hatásának vizsgálata állatkísérletes fájdalommodellekben. 
Magyar Fájdalom Társaság Kongresszusa, Siófok, 2005.  
Helyes Zs, Sándor K, Pintér E, et al. A szelektív szomatosztatin 4 receptor (sst4) 
agonista J-2156 gyulladásgátló és antinociceptív hatásának vizsgálata akut és 
krónikus gyulladásmodellekben. Magyar Kísérletes és Klinikai Farmakológus 
Társaság V. Konferenciája, Debrecen, 2005.  
Elekes K, Helyes Zs, Németh J, et al. A kapszaicin-érzékeny érzőideg végződések 
szerepe az endotoxinnal kiváltott légúti gyulladásban. Magyar Kísérletes és 
Klinikai Farmakológus Társaság V. Konferenciája, Debrecen, 2005.  
Helyes Zs, Pintér E, Németh J, et al. Effects of the novel selective non-peptide 
somatostatin sst4 receptor agonist J-2156 on sensory neuropeptide release and 
acute inflammatory reactions. A Magyar Farmakológiai Társaság 
Experimentális Szekciójának II. vándorgyűlése, Pécs, 2006.  
Elekes K, Pozsgai G, Pintér E, et al. Szelektív szomatoszatin sst4 receptor agonista J-
2156 hatásának vizsgálata egér légúti gyulladás modellekben. A Magyar 
Farmakológiai Társaság Experimentális Szekciójának II. vándorgyűlése, 
Pécs, 2006.  
Pozsgai G, Sándor K, Perkecz A, Brain SD, Szolcsányi J, Pintér E. Phorbol 12-
myristate 13-acetate (PMA) induced ear inflammation in transient receptor 
potencial vanilloid 1 (TRPV1) receptor transgenic mice. A Magyar 
Farmakológiai Társaság Experimentális Szekciójának II. vándorgyűlése, 
Pécs, 2006.  
Szabó Á, Czirják L, László T, et al. A TRPV1 receptor szerepének vizsgálata 
bleomycin-indukálta scleroderma egérmodellben. A Magyar Farmakológiai 
Társaság Experimentális Szekciójának II. vándorgyűlése, Pécs, 2006.  
Helyes Zs, Elekes K, Sándor K, et al. A kapszaicin-érzékeny érzőideg végződések és 
a TRPV1 kapszaicin receptor szerepének vizsgálata akut és krónikus légúti 
gyulladás modellekben. Magyar Gyulladásbiológiai Társaság I. Ülése, 
Balatonöszöd, 2006.  
 97 
Elekes K, Pozsgai G, Sándor K, et al. A szomatosztatin 4 receptor-altípus (sst4) 
szerepe endotoxin-kiváltotta légúti gyulladásban: in vivo génhiányos 
egerekben. A Magyar Experimentális Farmakológia III. Szimpóziuma, 
Budapest, 2007.  
Helyes Zs, Pintér E, Sándor K, Pozsgai G, Szolcsányi J. A szomatosztatin 4 receptor 
(sst-4) gátló szerepe rágcsálókban carrageeninnel kiváltott 
gyulladásmodellekben. A Magyar Experimentális Farmakológia III. 
Szimpóziuma, Budapest, 2007.  
Pozsgai G, Sándor K, Perkecz A, et al. Lokális aceton kezelés képes neurogén 
ödémát okozni érzékenyített egérfülön. In vivo vizsgálat TRPV1 receptor 
knockout egereken. A Magyar Experimentális Farmakológia III. 
Szimpóziuma, Budapest, 2007.  
Börzsei R, Pozsgai G, Bagoly T, et al. Inhibitory action of endomorphin-1, an 
endogenous opioid peptide, on sensory neuropeptide release and neurogenic 
inflammation in rats and mice. A Magyar Experimentális Farmakológia III. 
Szimpóziuma, Budapest, 2007.  
 
